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Abstract 
Liver sinusoidal endothelial cells (LSECs) constitute organ-specific microvascular 
endothelial cells (ECs) with unique phenotypical and functional characteristics. They form 
a discontinuous endothelial sheet at the interface between the blood stream and the 
hepatocytes and are the most permeable vascular barrier of the mammalian body. LSECs 
express endocytosis receptors that clear blood borne waste molecules and ensure thereby 
tissue homeostasis. Under pathological conditions they participate in development and 
progression of chronic liver diseases or promote liver regeneration through secretion of 
angiocrine factors.  
So far, most of LSEC research performed with mouse models relies on transgenic mice that 
demonstrated off-target effects in a variety of vascular beds. In vitro cell culture 
techniques only enable short-term cultivation of LSECs due to the subsequent 
dedifferentiation and are therefore of limited utility. To target the microvasculature of the 
liver more specifically transgenic mouse models were generated in which the 
bacteriophage-derived recombinase Cre is controlled by promoter elements of LSEC 
characteristic proteins. Two different founders of the Stab2-cre mouse and one founder of 
the Clec4g-cre mouse were characterised by reporter mouse models. All of three 
transgenic mouse lines demonstrated recombination in LSECs, but also in arterial and 
venous liver ECs. Apart from the liver, the Stab2- and Clec4g-cre mice target sinusoidal 
endothelial beds of other organs. A transgene activity in subpopulations of haematopoietic 
cells has been observed in two of three mouse lines. The pattern of Cre activity was time-
dependent. Stab2-cre founder 2 mouse for example showed sinusoidal EC activity during 
development that broadened to most ECs in other organs during adulthood. Therefore, the 
transgenic mouse models can be advantageous when manipulating LSEC specific protein 
expression or using them for cell fate tracking. An appropriate model should be selected 
depending on the gene of interest and the developmental period to be investigated. In 
comparison to conventional and inducible endothelial transgenic mouse lines these mouse 
models exhibit reduced off-target effects in ECs of other organs and homogenous Cre 
activity in LSECs, respectively. 
GATA4 was identified in a cluster of transcription factors (TFs) overexpressed in rat LSECs 
compared to rat lung microvascular ECs. GATA4 has a fundamental role during cardiac 
development and in cardiac ECs precluding the analysis of GATA4 in LSECs by 
conventional endothelial Tek- or Cdh5-cre mice. Consequently, investigation of the 
function of GATA4 in LSECs required a transgenic mouse line that would induce GATA4 
loss in LSECs but not in the developing heart. Therefore, Stab2-cre founder 2 mouse was 
utilised to generate a conditional GATA4 knockout in LSECs. The knockout mouse 
demonstrated embryonic lethality with a reduced size of the fetal liver (FL) and a 
impaired hepatic vasculature. The FL endothelium transformed from discontinuous liver 
sinusoids to continuous capillaries. The capillarized ECs impaired the immigration of 
haematopoietic stem and progenitor cells (HSPCs) into the FL leading to lethal anaemia. 
Together, the data identify GATA4 as a master regulator for liver sinusoidal EC 
specification and for acquisition of organ-specific vascular competence supporting liver 
development. Finally, the results establish a role of the FL sinusoidal endothelium on 
maturation of HSPCs.  
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Zusammenfassung 
Lebersinusendothelzellen sind organspezifische mikrovaskuläre Blutgefäßzellen mit 
einzigartigen phänotypischen und funktionellen Merkmalen. Sie bilden ein 
diskontinuierliches Endothelzellblatt an der Grenze zwischen dem Blutstrom und den 
Hepatozyten und sind die durchlässigste vaskuläre Barriere im Säugetierkörper. 
Lebersinusendothelzellen exprimieren Endozytose-Rezeptoren, die durch Blut 
übertragene Abfallmoleküle klären und dadurch die Gewebehomöostase sicherstellen. 
Unter pathologischen Bedingungen sind sie an der Entwicklung und an der Progression 
von chronischen Lebererkrankungen beteiligt, oder fördern die Leberregeneration durch 
die Sekretion von angiokrinen Faktoren. 
Bisher basierte der Großteil der Lebersinusendothelzellforschung mit Mausmodellen auf 
transgenen Mäusen, die „Off-Target-Effekte“ in einer Vielzahl von Gefäßbetten zeigten. In-
vitro-Zellkulturtechniken ermöglichen aufgrund der nachfolgenden Dedifferenzierung nur 
eine kurzfristige Kultivierung von Lebersinusendothelzellen und sind daher nur von 
begrenztem Nutzen. Um gezielt die kleinen Blutgefäße der Leber anzusteuern, wurden 
spezifisch transgene Mausmodelle erzeugt, in denen die von Bakteriophagen stammende 
Rekombinase Cre durch Promotorelemente von lebersinusendothelzellcharakteristischen 
Proteinen kontrolliert wird. Zwei verschiedene Gründer der Stab2-cre-Maus und ein 
Gründer der Clec4g-cre-Maus wurden durch Reporter-Mausmodelle charakterisiert. Alle 
drei transgenen Mauslinien zeigten eine Rekombination in Lebersinusendothelzellen, aber 
auch in arteriellen und venösen Leberendothelzellen. Neben der Leber steuern die Stab2- 
und Clec4g-cre-Mäuse Sinusendothelzellen anderer Organe an. In zwei von drei 
Mauslinien wurde eine Transgenaktivität in Subpopulationen von hämatopoetischen 
Zellen beobachtet. Das Muster der Cre-Aktivität war zeitabhängig. Beispielsweise zeigte 
die Stab2-cre Gründermaus 2 während der Entwicklung eine Aktivität in 
Sinusendothelzellen, die sich im Erwachsenenalter auf die meisten Blutgefäßzellen in 
anderen Organen ausweitete. Die transgenen Mausmodelle können daher vorteilhaft sein, 
um die lebersinusendothelzellspezifische Proteinexpression zu manipulieren oder um das 
Zellschicksal nachzuverfolgen. Ein geeignetes Modell sollte in Abhängigkeit von dem zu 
interessierenden Gen und der zu untersuchenden Entwicklungsperiode ausgewählt 
werden. Im Vergleich zu konventionellen und induzierbaren endothelialen transgenen 
Mauslinien zeigen diese Mausmodelle reduzierte „Off-Target-Effekte“ in Blutgefäßzellen 
anderer Organe bzw. homogenere Cre-Aktivität in Lebersinusendothelzellen. 
GATA4 wurde in einem Cluster von Transkriptionsfaktoren identifiziert, die -im Vergleich 
zu mikrovaskulären Blutgefäßzellen der Rattenlunge- in Lebersinusendothelzellen der 
Ratte überexprimiert waren. GATA4 spielt eine fundamentale Rolle bei der 
Herzentwicklung und in kardialen Blutgefäßzellen, was die Analyse von GATA4 in 
Lebersinusendothelzellen durch konventionelle endotheliale Tek- oder Cdh5-cre-Mäuse 
ausschloss. Folglich erforderte die Untersuchung der Funktion von GATA4 in 
Lebersinusendothelzellen eine transgene Mauslinie, die einen GATA4-Verlust in 
Lebersinusendothelzellen induzieren würde, jedoch nicht in dem sich entwickelnden 
Herzen. Daher wurde Stab2-cre Gründermaus 2 verwendet, um einen bedingten GATA4 
Knockout in Lebersinusendothelzellen zu generieren. Die Knockout-Maus zeigte eine 
embryonale Letalität mit einer reduzierten Größe der fetalen Leber und einem 
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beschädigten Lebergefäßsystem. Das fetale Leberendothel transformierte von 
diskontinuierlichen Lebersinusoiden in kontinuierliche Kapillare. Das kapillarisierten 
Gefäß beeinträchtigte die Einwanderung von hämatopoetischen Stamm- und 
Vorläuferzellen in die fetale Leber, was zur letalen Anämie führte. Zusammengenommen 
identifizieren die Daten GATA4 als Hauptregulator für die Spezifikation der 
Lebersinusendothelzellen und für den Erwerb von organspezifischer Gefäßkompetenz, die 
die Leberentwicklung unterstützt. Zu guter Letzt zeigen die Ergebnisse eine Rolle der 
sinusoidalen fetalen Leberblutgefäßzellen bei der Reifung von hämatopoetischen Stamm- 
und Vorläuferzellen. 
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1. Introduction 
1.1. Vasculature 
The vasculature forms a hierarchical network that extends through the organism and 
connects thereby distant organs and supports the underlying tissues. The inner lining is 
formed by ECs which vary enormously in structure and morphology to ensure proper 
function (Figure 1). The vasculature can be classified in macro- and microvasculature and 
will be discussed more in detail in the following section.   
 
 
Figure 1: Organization and anatomy of the vasculature. 
The hierarchical vascular network is comprised of arteries, veins, and interconnected capillaries as well as 
the lymphatic system.  The macrovascular system (bottom of the image) connects distant organs whereas 
the microvasculature (top of the image) including arterioles, capillaries and venules, interacts with the 
underlying tissue. ECs - endothelial cells, BM - basement membrane; SMCs - smooth muscle cells. From 
Potente and Mäkinen 1.
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1.1.1. Macrovasculature 
The macrovascular system comprises the large vessels and with a diameter of more than 
100 µm. The following section gives a brief overview about arterial and venous as well as 
lymphatic vessels.  
 
1.1.1.1. Arterial and venous vessels 
Arteries and veins constitute the macrovascular system. They are characterized by a 
continuous lining of ECs, a basement membrane  and layers of smooth muscle cells (Figure 
1) 1. Arteries have thick walls and pulsate. The long and narrow ECs are lined in the 
direction of the blood flow and are characterized by tight inter-cellular junctions. Typical 
markers include ephrinB2, Delta-like ligand 4, neuropilin 1, Hey1 and Hey2. Veins, on the 
contrary, have thin walls, valves, and do not pulsate. The ECs are shorter and wider and 
are lined opposite to the blood flow. The tight junctions are less complex with regard to 
the inter-cellular molecules and protein composition. Specific markers include ephrinB4, 
neuropilin 2 and COUP-TF 2 2. Arteries transport well oxygenated blood to the organs and 
veins collect low-oxygenated blood from the organs, except for the pulmonary circulation, 
where the situation is reversed and arteries transport low-oxygenated blood and veins 
transport well oxygenated blood. 3.  
 
1.1.1.2. Lymphatic vessels 
Lymphatic vessels transport fluids from the pre-collecting lymphatic vessels and the 
microvascular lymphatic capillaries. The lymphatic system is coupled to the blood 
vascular system as extravasated fluid and macromolecules are collected and returned to 
the blood circulation at the left venous angle 1. Lymphatic ECs of the vessels are 
characterised by a continuous basement membrane and perivascular smooth muscle cells 
which form zipper-like junctions that prevent leakage and ensure proper delivery to the 
lymph nodes (LNs) (Figure 1). The luminal valves are comprised of ECs with a unique 
spindle-like morphology that prevents retrograde lymph flow. Although lymphatic vessels 
are predominantly involved in immune cell trafficking they also play a role in intestinal fat 
absorption and cholesterol transport 4. Compared to the blood vascular system, the 
lymphatic flow is slow and irregular and the transport is unidirectional. Lymphatic ECs 
derive from venous EC and their development is regulated by the TF PROX-1. Typical 
markers include, besides PROX-1, lymphatic vessel endothelial hyaluronan receptor 1 
(LYVE1) and podoplanin.  
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1.1.2. Microvasculature 
Opposite to the macrovascular system, which is responsible for the transfer of solutes to 
distant body parts, the microvasculature comprises vessels with smaller diameter that 
participate in the microcirculation of tissues and organs. Besides the microvascular 
lymphatic capillaries, the microvasculature comprises arterioles, venules and capillaries 
(Figure 1). Arterioles branch from the arteries into the capillaries and function in the 
regulation of the vascular tone, whereas venules collect blood from the capillaries and 
drain into the veins 1. With a diameter of less than 10 µm and a thin wall consisting of only 
one layer of ECs the capillaries possess the largest surface of the vasculature and are 
responsible for the major exchange between blood and organ. Capillaries display the most 
diverse phenotype within the vascular tree as they vary in structure and function and are 
highly adopted towards the need of the underlying tissue. As a result, the phenotype of the 
capillaries may be continuous and either non-fenestrated or fenestrated, or discontinuous 
2. 
 
1.1.2.1. Continuous, non-fenestrated capillaries 
Continuous, non-fenestrated capillaries are typically found in the heart, lung, and blood 
brain barrier. They are characterised on the abluminal side by the presence of a 
continuous basement layer that is 60 to 100 nm thick, composed of collagen type IV 
proteins and glycoproteins. On the luminal side an anionic glycocalyx matrix layer 
contributes to the endothelial barrier function. The transvascular flow occurs either via 
tight connected interendothelial clefts that allow for the passage of molecules with less 
than 1 nm in diameter 5 or via caveolae that transport larger substances 6. High abundance 
of the junctional protein platelet endothelial cell adhesion molecule, also known as CD31, 
and expression of the basement membrane protein collagen IV enables the identification 
of continuous, non-fenestrated capillaries by immunological staining procedures.  
Thus, continuous, non-fenestrated capillaries contribute to a restricted exchange of 
substance between the blood stream and the underlying tissue.  
 
1.1.2.2. Continuous, fenestrated capillaries 
Continuous, fenestrated capillaries are predominantly found in endocrine glands, 
intestinal mucosa and kidney glomeruli. Similar to the continuous, non-fenestrated 
capillaries they possess on the abluminal side a continuous basement membrane and on 
the luminal side an anionic glycocalyx matrix. Additionally, they are equipped with 
transcellular pores, so called fenestrations, which extend completely through the cell and 
are of approximately 70 nm in diameter. The majority of those fenestrae possess a non-
membranous diaphragm across their opening which contributes to an increased 
permeability of small solutes and increases the size selectivity of transported substances. 
The density of fenestrations in EC vary between the vascular beds, in the rat jejunum for 
example the fenestral density is almost twice as high as in the pancreas 6. The diaphragm 
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is mainly composed of the plasmalemma vesicle-associated protein (PLVAP) and is 
induced by vascular endothelial growth factor (VEGF) 5. 
Thus, the presence of fenestrated EC enhances the transcellular flow and contributes to an 
increased filtration and transendothelial transport.  
 
1.1.2.3. Discontinuous capillaries 
Discontinuous capillaries, also known as sinusoids, are found in the bone marrow (BM), 
liver, LN, and spleen. They discriminate from the continuous capillary type by the lack of a 
basement membrane and a thin or partly irregular luminal glycocalyx layer 5. 
Characteristics of sinusoidal EC in the BM, liver, LN, and spleen will be elaborated in the 
following section. 
 
1.1.2.3.1. Bone marrow 
The BM is the primary site for haematopoiesis in the adult organism and apart of delivery 
of oxygen and nutrients, the blood vessels serve as a vascular niche to support 
maintenance and differentiation of HSPCs. Two types of microvasculature, namely 
arterioles and sinusoidal EC, were observed to affect HSPCs different and were 
investigated by Itkin et al. in 2016 7. The BM sinusoids were characterised by low levels or 
lack of adherens and tight junction molecules VE-Cadherin and zona occudens-1, high 
levels of E-selectin and a diameter of 25 µm compared to a diameter of 5 µm in BM 
arterioles.  Cells with high intracellular reactive oxygen species levels that induce HSPC 
mobilization and differentiation were detected adjacent to BM sinusoids. The lower blood 
flow due to the wider vessel lumen, the higher permeability due to fenestrations and loose 
junctions define the BM sinusoids as the exclusive site of rolling and adhesion of 
haematopoietic cells as well as transendothelial migration of mature leukocytes and 
immature HSPCs opposite to the BM arterioles which sustain HSPC quiescence. 
 
1.1.2.3.2. Liver 
The liver is responsible for the clearance of the blood and immune surveillance. The 
discontinuous capillaries in the liver form a sinusoidal network in which well-oxygenated 
blood from the hepatic artery and low-oxygenated, nutrient rich blood from the portal 
vein (PV) merges and drains into the central vein (CV). The sinusoids of liver will be 
discussed in more detail in section 1.1.3.   
 
1.1.2.3.3. Lymph node 
The LNs participate in the immune defence and are characterised by a network of 
lymphatic sinuses in close contact to immune cells and stromal cells. The lymph arrives via 
the afferent vessels into the subcapsular sinus, is transported to the cortical and medullary 
sinus and exits the LN via the efferent lymphatic vessels. High-endothelial venules (HEVs) 
represent the entry site for circulating lymphocytes 4. The LN sinuses are composed of two 
major cell types, the discontinuous EC and macrophages, which express a unique set of 
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scavenger receptors and lectin like proteins. By a comparative gene expression profiling 
and immunohistochemistry Martens et al. described Stabilin- (Stab)2 to be exclusively 
expressed by sinusoidal EC, whereas other molecules, such as LYVE1 or CD169, showed an 
expression by both cell types lining the LN sinuses. The receptors mediated the binding 
and endocytosis of hyaluronan and carbohydrate structures which were increased or 
aberrant expressed on tumour cells, respectively. As a result, the LN sinuses participate in 
the clearance of antigens or adhesion of tumour cells during metastasis progression 8. A 
study published by Iftakhar-E-Khuda et al. compared the transcriptome of ECs  lining the 
sinuses of afferent and efferent lymphatic capillaries 9. The authors identified CD169 and 
the macrophage scavenger receptor 1 to be exclusively expressed by the sinusoids of the 
subcapsular sinus whereas Endomucin was shown to be specific for sinusoidal EC of the 
cortical and medullary sinus. This differential protein expression pattern supported the 
function of the afferent lymphatic vessel to mediate the binding of lymphocytes and 
controlling thereby the entry into the parenchyma.  
 
1.1.2.3.4. Spleen 
The spleen collects antigen from the blood, is involved in immune responses to blood-
borne pathogens and participates in the recycling of iron and in b-cell maturation 10. The 
incoming blood drains via a network of branching arterial vessels into smaller arterioles 
and is then transported into venous sinusoids. Two distinct anatomic structures are 
present in the spleen, the white and the red pulp, separated by the marginal zone. The 
white pulp shows smaller branches of arterial capillaries and comprises the t-cell zone and 
b-cell follicle and promotes thereby a large interface for the immune defence. Most arterial 
capillaries terminate into the splenic sinusoids in the red pulp 11. Characteristically, the 
sinusoidal ECs in the red pulp have a discontinuous phenotype but comprise a thin anionic 
glycocalyx and show low levels of phago-endocytosis. Sinusoidal ECs have a cuboidal 
phenotype and the interendothelial junctions are located at the apical and basal side up to 
3 µm apart. On the abluminal side, stress fibres run in parallel to the cellular axis and 
connect the EC to the extracellular matrix (ECM) and guide erythrocytes into the sinuses 
through the interendothelial slits 5. 
 
  
Introduction 
6 
 
1.1.3. Liver sinusoidal endothelial cells 
The liver receives blood from the arterial and venous vessels which is then filtered by the 
sinusoids and exits through the CV. The liver is comprised of the liver parenchymal cells, 
the hepatocytes, the non-parenchymal cells, including the Kupffer cells, stellate cells and 
sinusoidal ECs, and the biliary epithelial cells. LSECs separate the blood stream from the 
hepatocytes and are characterised by the perisinusoidal space, the so-called space of 
Dissé, in which the stellate cells reside, whereas the Kupffer cells, the liver resident 
macrophages, patrol in the lumen of the sinusoids (Figure 2) 12 . 
 
 
 
Figure 2: Schematic view of the sinusoids in the mammalian liver.
Blood drains from the PV and the hepatic artery in the liver sinusoids and leaves through the CV. The bile 
runs in the opposite direction and is collected in the bile duct. The liver resident macrophages, Kupffer cells, 
the ECs and the hepatic stellate cells constitute the sinusoids. The space of Dissé separates the LSECs and 
the hepatocytes. HSC – hepatic stellate cells. From Iwakiri et al. 13
 
1.1.3.1. Phenotypical features 
The LSECs comprise approximately 50% of the non-parenchymal cells of the liver. They 
are characterised by open fenestrations that occupy 6% to 8% of the endothelial surface, 
are of 100 – 150 nm in diameter and arranged in sieve plates. LSECs are connected by 
intercellular junctions, display no gaps 14, lack a basement membrane and are devoid of a 
glycocalyx matrix fibres within the fenestrae 2. 
The presence of fenestrations in LSECs correlate with the presence of membrane rafts 15, 
so called microdomains in the cell membrane 16. Svistounov et al. 15 applied three-
dimensional structured illumination fluorescence light microscopy to investigate 
fenestrations in a primary culture of LSECs. Membrane rafts appeared in the perinuclear 
region in contrast to the fenestrations that were observed in the cellular periphery. 
Following treatment with several drugs, the numbers of membrane rafts were increased 
or decreased leading to a decrease or increase in the formation of fenestrations, 
respectively. By that the authors demonstrated an inverse relationship of membrane rafts 
and fenestrations and improved the understanding of those highly dynamic structures 15.  
Typically, if studying LSECs ex vivo one encounters the problem that LSECs are 
difficult to isolate and rapidly lose their phenotype upon culture. Several methods 
regarding isolation from human, rat, porcine, or murine livers were published over the last 
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years and were critically discussed by the community 14. Some of the points of criticism 
included that the antibodies applied for isolation were not commercially available 17, the 
isolation resulted in impurities 18 or markers for isolation were not chosen properly 19. 
Similar controversy occurs with regard to the cultivation of LSECs 14. Few scientists claim 
that LSECs can be cultivated and can be applied for experiments from a commercially 
available cell line 20 which is in contrast to the claim that LSECs die upon culture due to 
toxic effects of the serum supplemented to the growth medium 21, or that LSECs cannot be 
cultivated due to the lack of the liver specific microenvironment 22. The latter statement is 
supported by several publications that demonstrate a decrease or loss of fenestrations 
already after one day in culture 14,23, loss of marker protein expression upon cultivation 24 
and an impaired ability to perform endocytosis after several days in culture 25. In order to 
circumvent these problems, one can either utilize LSECs for the analysis within a few 
hours after isolation, use tissue sections or apply in vivo methods to study LSEC functions. 
In a comprehensive study Géraud et al. analysed the molecular components of 
LSEC junctions on human and rat liver sections 26. Adherens junctions are cell-cell 
connections that are directly linked to the actin cytoskeleton 16 and were observed in 
LSECs by the high abundance of VE-Cadherin and the intracellular interaction partners α- 
and β-catenin as well as p120 catenin and plakoglobin. Tight junctional protein complexes 
function as barrier between neighbouring ECs 16 and are typically not found in human and 
rat liver sinusoids which was evident by the absence of occludin. However, the junctional 
adhesion molecule A was expressed in human and rat LSECs 26. Therefore, LSECs can be 
identified by the classical adherens junction molecules, such as VE-Cadherin or β-catenin, 
or by the tight junction protein junctional adhesion molecule A. In addition to that, LSECs 
express cell surface marker that are also found in other sinusoidal capillary beds, like 
Stab2 27 or LYVE1 8.  
 
1.1.3.2. Origin and formation  
During the 80s and 90s, new insights in the field of liver development derived from 
ultrastructural analysis in human, rat, and mouse FLs. By using electron microscopy, the 
formation of the liver sinusoids was monitored during onset of liver organogenesis or 
during the phase of liver growth. Despite differences regarding the presence of 
fenestrations or gaps, the FLs showed remarkably common characteristics across 
mammalian species. During onset of liver formation, the sinusoids of the rat FL 
demonstrated a continuous EC lining, which were devoid of a basal lamina and had low 
numbers of diaphragmed fenestrations 28. Murine sinusoids were characterised by a 
continuous sheet of ECs with the presence of tight junctional complexes 29. In human, the 
primitive intrahepatic capillaries were defined as CD31+ ECs between the hepatic cords 
which differentiated into CD31low Lamininlow sinusoids or into CD31+ Laminin+ PV EC 
during onset of liver formation 30. In the phase of liver growth, the sinusoids of fetal rat 
liver were still lined by continuous EC with diaphragmed fenestrations that were then 
gradually outnumbered until birth by fenestrations without diaphragms 28. The murine 
sinusoids started to adopt a discontinuous endothelial phenotype with partially 
fenestrations 29. In human, the phenotype of the FL vasculature resembles the adult 
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phenotype as sinusoidal ECs completely lack CD31 and Laminin expression 30. Human, rat 
and mouse LSECs show hereby a high degree of plasticity because the liver sinusoids 
switch from a continuous to discontinuous endothelial phenotype during gestation.  
Despite their continuous phenotype, the FL sinusoidal capillaries already express marker 
of adult LSECs 31. The first ECs of the developing liver showed no vascular lumen and 
occasionally expressed Stab2. The increase of sinusoidal EC within the FL was 
accompanied by an increase of LYVE1 and Stab2 expression. During liver growth, Stab2+ 
and LYVE1+ EC were observed in the fetal sinusoids as well as in the large vessels, 
nevertheless, expression of LYVE1 and Stab2 in arterial and venous EC was diminished 
after birth.  
Combination several transgenic mouse models allowed Zhang et al. to track liver ECs 
during development and demonstrated that the liver vasculature is derived from 
endocardial cells of the sinuous venosus 32. The authors showed that during onset of liver 
formation, descendants of endocardial cells were involved in the formation of the initial 
liver endothelium. The cells accounted for approximately 40% of the liver EC during liver 
growth and persisted until the adulthood. Timed induction of the reporter system proved 
that the descendant cells contributed to the liver vasculature during the time of formation 
of the liver bud indicating a common endothelial origin hepatic and cardiac ECs. 
 
1.1.3.3. Functional characteristics 
LSECs possess high a phago-endocytic capacity which is facilitated by the expression of 
endocytosis receptors. So far, three main types of endocytosis receptors have been 
described in LSECs, the scavenger receptor, the mannose-receptor and the Fc-gamma 
receptor 33. The mannose-receptor, CD206, binds to terminal mannose residues and 
internalizes substrates in a Ca2+ dependant manner. CD206 consists of an N-terminal 
cysteine-rich domain, a fibronectin type II domain, and several C-type lectin-like domains 
34. The Fc-gamma receptor IIb, CD32b,  is involved in the binding and uptake of the Fc 
domain of immunoglobulin G and participates thereby in immunological functions 33. The 
extracellular part of CD32b consists of two highly glycosylated Ig-like domains and the 
intracellular part is characterised by an immunoreceptor tyrosine-based inhibition motif 
35. Of the scavenger receptors, a variety has been discovered to be expressed in LSECs or in 
other cell types such as macrophages, dendritic cells or natural killer cells. Based on their 
function they were classified into ten groups (SR-A to SR-J) 36. The macrophage scavenger 
receptor type I and II belong to the class A scavenger receptors, SR-A, and is a 
homotrimeric transmembrane protein with an extracellular scavenger receptor cysteine-
rich domain and a collagen-like domain 37. In LSECs, it internalises β-amyloid, heat shock 
proteins, surface molecules of Gram-positive and Gram-negative bacteria, and hepatitis C 
viruses 38. The platelet glycoprotein 4 belongs to the class B scavenger receptors, SR-B, 36 
and consists of two short intracellular domains at both termini and a large extracellular 
domain with a hydrophobic sequence where lipid ligands bind 39. Besides fatty acid 
uptake, it facilitates the internalisation of apoptotic cells and amyloid proteins 40. The 
hyaluronan receptors Stab1 and Stab2 are grouped into the class H scavenger receptors, 
SR-H 36. Stab1 and Stab2 are both multidomain proteins consisting of fasciclin, epidermal 
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growth factor- (EGF) like and Laminin-type EGF-like domains as well as a linker region 
and share about 40% homology 41. Stab2 is the primary receptor for hyaluronan and is 
responsible for the uptake of heparin, chondroitin sulphate, dermatan sulphate, non-
glycosaminoglycan, acetylated low-density lipoprotein, pro-collagen propeptides and 
advanced glycation end products 42,43. Stab1 mediates the endocytosis of acetylated low-
density lipoprotein, Gram-positive and Gram-negative bacteria 41,42,44. Other receptors 
with known scavenging functions are for example the c-type lectin domain family 4 
member G (CLEC4G) or LYVE1.  
Implication of the scavenger receptors on tissue homeostasis was emphasized by 
Schledzewski et al. who genetically inactivated the hyaluronan receptors Stab1 and Stab2 
45. While single knockouts of Stab1 or Stab2 did not cause any gross abnormalities, the 
double knockout resulted in a decreased survival rate and a perisinusoidal liver fibrosis. 
Although no metabolic dysfunction of the liver was observed, the authors determined 
severe defects of the kidney function. Detailed analysis revealed a glomerular fibrosis and 
a proteinuria that was caused most likely by circulating, yet, unidentified factors.   
Over the past years, the liver sinusoidal endothelium became more and more recognised 
as key players in instructing neighbouring cells and participating in regeneration, 
metabolism and liver formation. Pioneering work in this field derived from S. Rafii and 
colleagues who defined the term ‘angiocrine’ as “vascular niche-derived paracrine factors” 
46 and emphasized the critical role of the endothelium on tissue homeostasis. LSECs 
secrete angiocrine factors and promote liver regeneration. Ding et al. demonstrated the 
contrasting function of the C-X-C chemokine receptors type 4 (CXCR-4) and type 7 (CXCR-
7) in LSECs during acute and chronic liver injury 47. After acute liver damage, CXCR7 
induced the upregulation of the TF Id1 that lead to a secretion of angiocrine factors from 
LSEC which were known to promote angiogenesis and trigger liver regeneration. After 
chronic liver damage, however, signalling from fibroblast growth factor (FGF) receptor 1 
induces upregulation of CXCR-4 which inhibited Id1 and caused an increase of ECM 
proteins and induced a pro-fibrotic niche. Besides the balance of CXCR-4 and CXCR-7 
signalling on liver regeneration, angiopoietin-2 was identified to control liver regeneration 
in a spatiotemporal manner 48. During the first phase of liver regeneration, hepatocyte 
proliferation was ensured by low levels of LSEC-derived angiopoietin-2. However, during 
the second phase of regeneration the increase of angiopoietin-2 expression from LSECs is 
necessary to promote angiogenesis. These findings underline LSECs as highly dynamic 
structures in orchestrating organ regeneration and highlight their function on liver 
homeostasis.  
 
1.1.3.4. Pathological aspects 
In a healthy and physiological surrounding, LSECs participate in a variety of processes. 
Under pathological conditions, however, LSECs can engage the initiation and progression 
of liver diseases, for example through the transformation of their sinusoidal phenotype, 
activation of quiescent stellate cells, or promotion of cancer progression 49.  
LSECs display a unique phenotype along the microvascular bed as they are characterised 
by fenestrations and discontinuity. Loss of these characteristics, i.e. the reduction of 
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fenestrations, the formation of a basement membrane and the change in the marker 
expression profile, is called capillarization in vivo or dedifferentiation in vitro. It classifies 
early events during various liver diseases and many researchers attempted to gain insight 
into the mechanism. However, if studying liver sinusoidal capillarization as an isolated 
process in mouse models, problems can occur due to secondary effects that distort the 
results. Lao et al. circumvented this pitfall by applying sodium arsenite to the mice which 
was reported to induce hepatic capillarization without the subsequent fibrotic events 50. 
Proteome profiling of treated versus untreated mice identified, among others, disabled 
homolog 2 (Dab2) to be upregulated in dedifferentiated LSECs. Dab2 mediates endocytosis 
of the VEGF receptor and the increased Dab2 expression correlated with an increased 
VEGF signalling as well as increased VEGF receptor endocytosis during dedifferentiation in 
LSECs. However, VEGF was reported to maintain LSEC differentiation 51, consequently Lao 
et al. hypothesized that the Dab2 mediated VEGF receptor endocytosis dominated over the 
VEGF concentration effect during LSEC dedifferentiation 50. 
Capillarization of LSECs is a result of toxic liver injury, non-alcoholic steatohepatitis or 
alcoholic liver injury and can progress further into chronic liver disease 52. The 
phenotypical liver fibrosis is characterised by an accumulation of ECM in the 
perisinusoidal and periportal area. Fibrosis can develop into cirrhosis or liver failure and 
is reversible until a specific time point after which the only effective treatment is liver 
transplantation 53. LSEC participate in the fibrotic events through activation of stellate 
cells which is characterised by an increase of α-smooth muscle actin and type I collagen 54. 
DeLeve demonstrated that if stellate cells were cultured alone, they became activated, but 
if stellate cells were co-cultured with differentiated LSECs, the activation was reversed, 
and if stellate cells were co-cultured either with dedifferentiated LSECs or with 
hepatocytes, the activation persisted. This indicated that LSECs sustained a quiescent 
stellate cells phenotype under physiological conditions and that dedifferentiated LSECs 
promoted stellate cell activation. LSEC-derived nitric oxide was a prerequisite to sustain 
stellate cell quiescence and was induced by VEGF from hepatocytes or stellate cells which 
emphasize the tightly regulated signalling events in the hepatic vascular niche.  
The final fate of chronic liver disease is in some cases hepatocellular carcinoma (HCC) and 
loss of the LSEC marker profile correlated with the disease outcome 55. In mouse models of 
HCC, loss of LSEC marker was observed in liver tumours and the extent of marker 
reduction correlates with the size of tumour nodules. Similarly, in liver samples from HCC 
patients LSEC markers were lost in the tumours. Analysis of the peritumoural tissue 
identified Stab2 to be less expressed and loss of peritumoural Stab2 was associated with 
an increase of the overall survival rate. The authors concluded that loss of specific marker 
expression in the progression of HCC could provide a tool to identify subsets of HCC and 
facilitate the prognosis and treatment of this severe cancer. 
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1.1.4. Targeting liver sinusoidal endothelial cells by transgenic mouse 
models 
Genetic manipulation of protein functions in vivo has considerable benefits compared to 
the investigation of protein functions in vitro. The discovery of new methods over the past 
decades facilitated the targeted depletion, modification or overexpression of genes and 
ribonucleic acid (RNA) molecules. In 1992, Orban et al. described a method that would 
allow the tissue- and/or site-specific DNA recombination 56. The Cre/loxP system utilizes 
the ability of the bacteriophage P1 derived Cre recombinase to recognize the loxP site, a 34 
base pairs (bp) long DNA sequence and to recombine two loxP sites. Depending on the 
orientation of the loxP sites, either as direct or as inverted repeats, the Cre recombinase is 
able to excise or to invert a DNA fragment, respectively. Flanking of promoter regions, 
exon fragments or whole coding sequences with loxP sites enables the targeted 
manipulation of proteins by a precise excision of gene fragments. The expression of the 
Cre recombinase does not have to be ubiquitous but can be restricted or targeted by 
promoters of proteins with known spatial or temporal activity. 
With a growing interest in the macro- and microvascular system, the number of available 
transgenic mice increases that allow for an endothelial specific activity of the Cre 
recombinase. Until today, three transgenic mouse models are accessible that are 
frequently used to target the sinusoidal endothelium of the liver. First, the Tek-cre 
transgenic mouse, published by Kisanuki et al. 57 that utilizes the promoter of the 
angiopoietin receptor Tie2 to drive the expression of the Cre recombinase in ECs. Second, 
the Cdh5-cre transgenic mouse, which was published by Alva et al. 58, that uses the 
promoter of the junctional molecule cadherin-5. Third, the flk-1-cre transgenic mouse, 
which was published by Licht et al. 59 that utilizes the promoter of the VEGF receptor 2, 
which fulfils a variety of functions in ECs. 
All three transgenic mouse models show an activity of the Cre recombinase in ECs from 
early fetal development onwards and target the complete macro- and microvasculature in 
all organs of the adult mouse. Therefore, a transgenic mouse model with activity 
selectively in the liver sinusoids has not been generated yet.  
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1.2. Liver organogenesis 
The liver is the largest internal organ with functions in metabolism as well as secretion 
from endocrine and exocrine glands. The hepatoblasts and biliary epithelium develop 
from the endodermal-derived foregut whereas sinusoidal ECs, Kupffer cells and stellate 
cells are rather mesodermal-derived cell types. In the following section, hepatic 
specification, liver growth and postnatal liver development will be described (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Time line of mouse liver development.  
The three germ layers are formed during gastrulation between embryonic day (E)6.5 and E7.5 The 
endoderm is patterned along the anterior-posterior axis which results in the separation of foregut (fg), 
midgut (mg), and hindgut (hg) around E8. The liver diverticulum (ld) emerges from the ventral foregut 
adjacent to the heart and expands to the liver bud (lb) at E9. From E10 onwards the liver growth and 
maturation proceeds into the postnatal stage. From Zorn 60 
 
1.2.1. Initiation of liver development  
During gastrulation, between embryonic day (E)6.5 and E7.5, the three germ layers 
(ectoderm, mesoderm, and endoderm) are formed from the inner cell mass and generate 
subsequently the definitive endoderm. Surrounded by the mesoderm and further anterior-
to-posterior patterning subspecialize the now ventral definitive endoderm into foregut, 
midgut, and hindgut 61. The closure of the foregut and morphogenetic movements of 
mesodermal layers at E8.5 positions the hepatic rudiment distant to cardiac mesoderm 
and close to the surrounding mesenchyme of the septum transversum 62. During this 
process important inductive cues derive from GATA4, Bone morphogenetic protein 
(BMP)4 and FGFs. Further signalling from the heart and mesenchyme initiate a transition 
from unspecified cells of the liver diverticulum into cells with a columnar morphology that 
start to express typical hepatocyte genes like Albumin or hepatocyte nuclear factor 
(HNF)4α. Approximately at E9, the liver diverticulum has transitioned into a 
pseudostratified epithelium that starts to delaminate and invade the surrounding stroma 
63. BMP signalling from the septum transversum mesenchyme (STM) plays a pivotal role 
during this process. The septum transversum mesenchymal cells, which contribute to the 
epicardium and diaphragm, promote outgrowth of the liver bud into the septum 
transversum. After colonization by hepatoblasts, cells from the STM and liver bud move 
toward the midgut and caudal to the developing heart 4. A research published by 
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Matsumoto et al. investigated the role of ECs on liver organogenesis prior to liver bud 
formation 65. They detected single ECs between the pseudostratified hepatic epithelium 
and the STM around E8.5. From E9.0 to E9.5, during delamination and invasion of the 
hepatic cord into the STM, single ECs started to organize into vascular structures and lined 
the nascent sinusoids from E9.5 onwards. Depletion of ECs from the embryos induced the 
formation of the liver diverticulum but the invasion in the STM was missing. By using 
explants experiments the authors could show that ECs are crucial for the growth of the 
hepatic mass. Consequently, Matsumoto et al. postulated a critical role for the nascent 
endothelium by providing angiocrine factors to stimulate proliferation of the hepatoblasts.  
 
1.2.2. Fetal liver haematopoiesis 
Immediately after formation of the liver bud the FL becomes the primary haematopoietic 
organ until birth when haematopoiesis shifts to the BM. Several haematopoietic waves 
take place during embryogenesis switching thereby anatomical locations in the embryo 
and ensuring by that the generation of a large number of haematopoietic cells with 
different pronounced differentiation states. In the first wave the FL is seeded by 
myeloerythroid progenitors that arose in the YS around E7.5 and entered circulation with 
the initiation of the heartbeat. The terminal differentiation takes place in the FL because 
the YS does not provide a proper niche for the final maturation. During the second wave 
definitive haematopoietic stem cells (HSCs) immigrate into the FL from the aorta-gonad-
mesonephros (AGM) region and the placenta. The AGM region consists of the ventral wall 
of the dorsal aorta, the genital ridges and the mesonephros and is the first intraembryonic 
site of haematopoiesis. Here, the definitive HSCs are sought to develop around E10.5. After 
E12.5 the FL becomes the only haematopoietic organ where HSCs proliferate and 
differentiate, however, the FL is not able to generate HSC de novo 66. The rapid expansion 
of the FL from E10.5 to E11.5 is primarily a consequence of the increase of haematopoietic 
activity. The relative amount of the haematopoietic cells increases from one third to three 
quarter of the total FL mass from E11.5 to E13.5 67. In order to gain a better understanding 
of the events that happen during initiation, peak, decline, and disappearance of the FL 
haematopoiesis Guo et al. investigated the FL at E11.5, E14.5, E15.5 and 3 days 
postpartum (dpp), respectively 68. The authors discovered more transcriptomic and 
proteomic differences between E14.5 and E15.5 than between E11.5 and E14.5 suggesting 
for a key step from E14.5 to E15.5. Between E11.5 and E14.5 genes involved in 
proliferation, maintenance or differentiation of haematopoietic cells were increased and 
genes involved in several metabolic functions were suppressed. From E14.5 to E15.5, 
haematopoietic activity was rapidly decreased and the FL displayed an increase of genes 
typical for the adult liver function including upregulation of genes associated with 
metabolism of carbohydrates, protein and fatty acids. This key point during maturation of 
the FL was characterized by a decreasing number of HSCs and a gain of transcriptional 
activity for metabolism-associated genes. The metabolic liver functions were restricted 
during the proliferation and differentiation phase of HSC and were subsequently expanded 
from E15.5 onwards which was accompanied by the differentiation from hepatoblasts to 
hepatocytes. Guo et al. hypothesized that both, the FL stromal cells and undifferentiated 
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hepatocytes, support and stimulate haematopoiesis by releasing cytokines or creating a 
hypoxic milieu.  
Since the haematopoietic progenitor cells (HPCs) from the YS or AGM region have to 
encounter first the endothelium before migrating into the FL the role of fetal LSECs during 
this process was investigated. In 2014, Dartsch et al. published a study about the effect of 
increased junctional stability of FL sinusoids on haematopoiesis 69. Junctional stability was 
manipulated by covalently linking vascular endothelial (VE-) cadherin to α-catenin which 
resulted in embryonic lethality during mid-gestation, a reduced FL size as well as an 
aberrant haematopoietic-to-hepatoblast ratio. Investigation of HSPCs revealed proper 
formation in the AGM region but an accumulation in the fetal blood. The authors observed 
a low number of HSPCs in the liver that were still able to differentiate into various 
haematopoietic lineages. Thus, the increased junctional stability of LSECs caused an 
impaired entry of HSPCs into the FL. 
 
1.2.3. Perinatal liver zonation 
During mid-gestation hepatoblasts are still bi-potent and are able to differentiate into 
hepatocytes or biliary epithelial cells. Around E13, FL cells that are in contact with the PV 
start to increase cytokeratin-19 expression and decrease hepatic genes. From E17 
onwards, the cells are surrounded by the portal mesenchyme and further formation of the 
intrahepatic bile ducts takes place until the perinatal period. Cells that are not in contact 
with the PV start to differentiate into hepatocytes which is triggered by signalling 
molecules secreted from haematopoietic cells. Around E17, hepatocytes adopt their 
characteristic morphology and are arranged in hepatic chords 60. During the prenatal 
phase the foetus is provided with nutrients from the maternal liver but after birth the 
hepatocytes perform metabolic functions. The organization of hepatocytes within the liver 
acini is thereby not uniform but rather are the hepatocytes distributed heterogeneously 
and are divided in zones according to their vicinity to the PV. Liver zonation is fully 
established at 10 dpp and is controlled by Wnt/β-catenin signalling which demonstrated 
the highest activity around the CV.  Since Rspondins (Rspo) were reported to regulate Wnt 
signalling activity, Rocha et al. studied the role of Rspo signalling on the formation of liver 
zonation 70. Expression of Rspo-3 was observed in liver ECs of the CV at E17 and remained 
until adulthood. Induced deletion of Rspo-3 during at E16.5 or after 8 weeks resulted in 
defects of the formation of the liver zonation with a characteristic abrogation of the 
periportal zonation pattern. Vice versa, ectopic expression of Rspo-1 reverses the effect of 
the Rspo-3 knockout and established an expansion of the pericentral zone. The authors 
concluded that the loss of Rspo signalling prevents pericentral differentiation which 
indicates a periportal gene expression profile in the hepatocytes as a default state.  
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1.3. The transcription factor GATA4 
Control of gene expression is a key element in different cell types and during development 
to adapt the repertoire of proteins and respond to external stimuli. Gene activity is 
regulated by TFs that bind to proximal or distant regulatory DNA elements and thereby 
activate or repress transcription. Classification of TFs into specific families and subfamilies 
is dependent on their DNA-binding domain which is mostly comprised of an α-helix that 
interacts with the major groove of the DNA. The zinc finger proteins are one of the major 
families of TFs and are named after the central Zn2+ ion in their conserved DNA binding 
motif 16. In the following section the GATA-binding TF family of zinc finger proteins are 
described more in detail with a main focus on GATA4. 
 
1.3.1. The family of GATA-binding transcription factors 
The first member of the mammalian family of GATA-binding TFs was described in 1988 by 
Evans et al. by the identification of GATA1 as an enhancer for the β-globin gene expression 
71. Over the years five additional homologues (GATA2/3/4/5/6) were discovered and 
grouped into two subfamilies based on their functional implications. GATA1/2/3 play a 
central role during differentiation of the haematopoietic system and GATA4/5/6 are 
involved in formation endodermal-derived organs. The GATA TFs are named after the 
consensus DNA sequence (A/T)GATA(A/G) which they recognise with a class IV zinc 
finger. In proteins with two zinc finger domains the C-terminal zinc finger binds the DNA 
whereas the N-terminal zinc finger regulates the DNA binding through interaction with co-
factors. The C-terminal zinc finger and basic domain are highly conserved throughout 
evolution in vertebrates, insects, Nematode, fungi, slime mould, and plant 72.  
 
1.3.2. Expression of GATA4 in the mouse 
The TF GATA4 was identified by Arceci et al. by using oligonucleotides that map the 
conserved region in the zinc finger domain in order to screen a complementary DNA 
(cDNA) library of murine embryo at E6.5 73. GATA4 differs from the GATA1/2/3 group 
through low sequence homology outside the zinc finger domain and the absence of 
binding to other GATA TFs. Northern Blot analysis revealed GATA4 messenger (m)RNA 
expression in the heart, ovary and testis and to a weaker extent in the lung, liver, and small 
intestine. By in situ hybridization, GATA4 transcripts were detected, among other things, 
in the fetal heart and primitive endoderm. In order to deepen the knowledge about GATA4 
expression during murine development a transgenic mouse was generated that harbours a 
knockin allele containing a DsRed2-IRES-cre expression cassette instead of the GATA4 
exon 2 to monitor endogenous GATA4 transcriptional activity 74. The initiation of reporter 
expression at E5.5 indicates a transcriptional start of GATA4 at the blastocyst stage. The 
authors could detect GATA4 messenger RNA (mRNA) by whole mount in situ 
hybridization in the inner cell mass at E4.5 indicating that GATA4 is involved in primitive 
endoderm differentiation. Application of several transgenic mouse lines demonstrated a 
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GATA4 expression in migratory neural crest cells and in subpopulations of neural crest 
stem cells.  
These studies show that GATA4 is expressed during pre-implantation period and is 
involved in cell fate decision in embryonic germ lines. Observation of GATA4 transcripts in 
heart, liver, lungs, gonads, and intestine inspired many researchers to study the function of 
GATA4 in those organs. Highlights of these studies are summarized in the following 
section.  
 
1.3.3. Critical role of GATA4 during development 
1.3.3.1. Cardiac development 
Two studies were published characterising the global GATA4 knockout. First, Kuo et al. 
generated a GATA4 genetic inactivation by replacing the first coding exon 75. The mutant 
embryos were characterised by an embryonic lethality around E8.5, absence of the heart 
tube, malformations of the gut and yolk sac (YS). No delay in development was observed. 
They concluded that GATA4 was not required for differentiation of cardiac myocytes or 
endocardial cells but instead for embryonic folding which is a prerequisite to generate the 
pericardial cavity, the heart tube, and the foregut. In a slightly different approach 
Molkentin et al. generated the global GATA4 knockout in the mouse 76. The replacement of 
exons encoding the zinc finger domains with a neomycin cassette resulted in a loss of 
functional GATA4 mRNA. Similar to Kuo et al., the embryos died around E9.5 with 
prominent cardiac defects and arrested in development. The authors concluded that 
GATA4 controlled lateral to ventral folding by regulating the migration of mesodermal 
precursors along the endoderm. Notably, the only difference between these studies is the 
use of a GATA4 transgenic mouse on C57BL/6 and SV129 mixed background by Molkentin 
et al. 76 or on a C57BL/6 and CD1/Agouti mixed background by Kuo et al. 75.  
Function of GATA4 on early heart specification was obvious but early embryonic lethality 
precluded the analysis during cardiac maturation. In order to elucidate the function of 
GATA4 in endocardial cells and endocardial-derived mesenchymal cells during 
cardiogenesis, Rivera-Feliciano et al. inactivated the GATA4 gene in ECs by using the Tek-
cre transgenic mouse 77. Functional GATA4 was absent in atrioventricular cushions at 
E11.5 which caused an embryonic lethality around E12.5 with peripheral haemorrhage 
and pericardial effusion in the mutant embryos (Figure 4). Notably, the mutant embryos 
showed a reduced FL size resulting either from the developmental defects of the heart or 
from Cre activity of the Tek-cre mouse in the FL. During formation the heart, the 
atrioventricular cushions develop into the atrioventricular valves which are essential for 
the proper separation of atrium and chamber. The decreased cellularity of the 
atrioventricular cushions in the mutant embryo was a result of an impaired 
transformation of the endocardium into an invasive mesenchyme which is a prerequisite 
for cushion formation. Explants and rescue experiments demonstrated a role of GATA4 on 
the regulation of Erbb3 expression in atrioventricular endothelium which induced the 
transformation of cardiac endothelium to mesenchymal cells. 
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Figure 4: Phenotype of embryos with endothelial-restricted inactivation of GATA4 (Gata4T2del).  
Gross appearance of E12.5 control and Gata4T2del littermates. Mutants showed liver hypoplasia (L) and 
variable growth retardation, peripheral haemorrhage and pericardial effusion (arrowhead).  From Rivera-
Feliciano et al. 77 
 
The interaction of GATA-4 with Friend of GATA (FOG) cofactors was investigated by 
Crispino et al. 78. The disrupted interaction of GATA4 with FOG-2 due to a single amino 
acid mutation caused an embryonic lethality around E12.5 and numerous defects in 
formation of the right ventricle and thicker endocardial cushions. 
GATA4 fulfils regulatory functions either during initiation of cardiac development 75,76 or 
during separation of the heart chambers 77–79. The studies give a small insight into the 
critical role of GATA4 during cardiogenesis but also highlight the influence of GATA4 as a 
main TF.  
 
1.3.3.2. Liver organogenesis  
One of the earliest studies that investigated the role of GATA4 on liver organogenesis was 
published by Rossi et al. in 2001 64. Apart from their main focus, the role of BMPs on 
induction of liver formation, the authors questioned, whether GATA4 expression in the 
nascent hepatic endoderm could be regulated by BMPs. Explants experiment with murine 
ventral foregut demonstrated that GATA4 mRNA was induced by BMPs. A GATA4 binding 
site at the enhancer of the albumin gene indicated a role for BMP4 and GATA4 in the 
endodermal liver induction.  
The function and expression pattern of GATA4 in the nascent liver bud was then 
investigated by Watt et al. 62.  Detailed analysis of the GATA4 protein showed an 
expression in the extraembryonic visceral endoderm, ventral foregut endoderm and 
cardiac mesoderm around E8.0. At E8.5, GATA4 expression decreased within the liver bud 
whereas the expression level in the neighbouring STM and ECs surrounding the liver bud 
persisted. At E9.0, during commitment of primary liver bud cells into the hepatic lineage, 
GATA4 expression was lost in hepatocyte progenitor cells but remained in the STM. 
Following genetic inactivation of GATA4, the growth and development of the liver bud was 
arrested although hepatic lineage differentiation had occurred. As endogenous GATA4 
expression was lost during expansion of the liver bud but was required for the growth of 
the liver bud in GATA4 knockout embryos the authors argued that GATA4 act in STM cells, 
cardiac mesodermal cells or ECs surrounding the liver bud. Since the STM was absent from 
the GATA4 knockout embryos, Watt et al. concluded that GATA4 plays a role in the 
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formation of the STM which was required for the subsequent expansion of the liver bud. 
This hypothesis was further investigated by the conditional inactivation of GATA4 in the 
STM 80. An STM-specific transcriptional enhancer of the GATA4 gene produced a 
transgenic Cre driver mouse (G2-Cre). Conditional deletion of GATA4 by the G2-Cre mouse 
caused an embryonic lethality at E13.5 with multiple defects in the FL including dilated 
sinusoids, decreased number of haematopoietic cells and reduction of proliferation and an 
increase of apoptosis in the hepatocyte. An increase of perisinusoidal collagen fibres and 
Laminin was observed from E13.5 onwards. An increase of Desmin+ and alpha smooth 
muscle actin+ cells in the FL of GATA4 knockout embryos indicated an activation of hepatic 
stellate cells. Detailed analysis revealed a decrease of the TF LHX2 which contains 
conserved GATA binding sites in the promoter region. After promoter binding studies, it 
was concluded that GATA4 controls the transcription of LHX2. Since the genetic 
inactivation of LHX2 led to similar fibrotic phenotype 81, Delgado et al. argued that the loss 
of GATA4 alters the transcriptional level of LHX2 provoking an hepatic stellate activation 
and fibrotic phenotype which impairs all together proper growth and development of the 
FL.   
The selected studies show a critical role of GATA4 during several steps of liver 
organogenesis. Rossi et al. 64 demonstrated a BMP4 dependent function of GATA4 in the 
stage of hepatic specification followed by Watt et al. 62 who postulated a direct role of 
GATA4 during growth of the liver bud and finally Delgado et al. 80 who emphasized a 
purpose GATA4 in the mesenchyme and mesenchymal-derived cells. 
 
1.3.4. GATA4 dysfunction in pathological processes 
GATA4 function during several stages of fetal development suggests a key role during 
initiation and progress of pathological conditions. There are several mutations of GATA4 
described which were associated with congenital heart diseases which is currently one of 
the major birth defects 82–84. Moreover, some researches have correlated loss or mutation 
of the GATA4 gene to HCC 85.  
 
1.3.4.1. Liver fibrosis  
Chronic damage to the liver and an accumulation of ECM proteins results in liver fibrosis 
which leads to cirrhosis and portal hypertension in case of a persisting injury 53. Delgado 
et al. reported a liver fibrosis in the embryo with an increase of ECM and activation of 
hepatic stellate cells 80. In the second part of their study, a role of GATA4 on fibrosis in a 
murine model of CCl4 induced fibrosis and on progression of the disease in human 
cirrhotic livers was investigated. Short-term treatment of mice with CCl4 induced a mild 
liver fibrosis in control mice that was more severe in mice heterozygous for GATA4. 
Examination of human liver samples with various stages of fibrosis or cirrhosis 
demonstrated a loss of GATA4 protein during the course of the disease progression. This 
showed a correlation of GATA4 levels in response to fibrotic injury and indicated that 
progression of fibrosis in human may be dependent on the GATA4 expression.  
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1.3.5. Function of GATA4 in non-mammals 
Transcriptional activity of GATA4 was also reported for non-mammalian organism, such 
as the fruit fly drosophila melanogaster, the frog Xenopus laevis, and the nematode 
Caenorhabditis elegans.  
Holtzinger and Evans investigated function of gata4 during development of the zebrafish 
86.  Treatment of fish embryos with gata4 morpholinos resulted in an improper looped 
heart, delay in development and absence of blood circulation. Later in development, the 
mutant fish embryos fail to initiate organogenesis of the intestine, liver, pancreas. Analysis 
of the liver development revealed proper formation of the liver bud and generation of 
hepatocytes but the liver bud failed to expand. Torregroza et al. continued the work on the 
characterization of the phenotype of the gata4 morphants and analysed the lack of blood 
circulation more in detail 87. As gata4 is not expressed in haematopoietic cells, the caudal 
haematopoietic tissue (CHT), a specialized region of the zebrafish that is necessary for 
initiation of the second haematopoietic wave, was investigated more in detail. Analysis of 
the vascularization of the CHT revealed a less branched vascular plexus and a reduced 
size. HPCs circulated in the gata4 morphants but were not able to seed the CHT. 
Investigation of stromal factors known to be involved for seeding of HSC identified the 
chemokine ligand sdf1a to show increased transcript levels. Since gata4 and sdf1a were 
both not expressed in the CHT, Torregroza et al. analysed at which time point gata4 was 
decisive and showed that the transcriptional activity of gata4 was needed during 
gastrulation to ensure proper CHT development and restrict levels of sdf1a. The authors 
proposed a role for gata4 and sdf1a in the establishment of haematopoietic niches since 
gata4 was linked to liver growth and sdf1a is a known chemoattractant for HPCs. 
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2. Aims of the thesis 
LSECs are unique organ-specific ECs that constitute the largest sinusoidal vascular bed of 
the body. LSECs are characterized by a characteristic gene expression profile that 
comprises transcription and growth factors as well as surface proteins involved in 
adhesion and endocytosis. The functional investigation of such specific genes of LSEC will 
often require Cre-mice that mediate genetic recombination in specific subgroups of ECs 
only to prevent off-target effects in other organs and other cells. Therefore, Aim1 of this 
thesis will focus on the generation and characterisation of such mice. In Aim2 these mice 
will be used to analyse the function of the TF GATA4 in mice with deletion of GATA4 in 
LSECs. This investigation could so far not be carried out as global endothelial deletion of 
GATA4 is lethal before liver development takes place. Aim2 therefore builds on Aim1 and 
provides proof of principle that the transgenic mouse generated in Aim1 provides an 
advantage to investigate organ-specific endothelial functions in vivo. 
 
Aim1 
Targeting liver sinusoidal endothelial cells by cell type-specific Cre driver mice 
The aim in this part of the PhD thesis is to characterise transgenic mouse lines with regard 
to their suitability to target LSECs and to critically evaluate their potential to generate a 
conditional knockout mouse. This will be achieved by the generation of the Stab2-cre and 
Clec4g-cre mice (1) and characterisation of the Cre activity by the respective reporter mice 
(2). The reporter will be analysed in LSECs of the fetal and adult mouse as well as in 
microvascular ECs of BM, LN and spleen and will be investigated in ECs and non-ECs of 
other organs. 
 
Aim2 
Function of GATA4 for the fetal development of liver sinusoidal endothelial cells 
In this part of the PhD thesis the implications of the conditional deletion of GATA4 in 
LSECs on embryonic and liver development will be analysed. In order to achieve this 
overall and liver development of the mutant embryos will be characterised (1), LSEC 
marker expression and endothelial ultrastructure of the FL will be analysed (2) and the FL 
haematopoiesis will be assessed by quantitative and qualitative methods (3). 
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3. Results 
3.1. Targeting liver sinusoidal endothelial cells – 
characterisation of LSEC-specific Cre driver mice 
3.1.1. The Stab2-cre mouse 
3.1.1.1. Generation of the transgenic Stab2-cre mice 
LSECs express a unique set of marker proteins of which the promoter element of Stab2 
was chosen to create an LSEC-specific Cre driver mouse strain (Stab2-cre). Strong protein 
expression of Stab2 was reported in endothelial sinuses of the liver 88–90, but as well in the 
spleen and the LN 27, and in the BM 91. Three founder mice were obtained of which two 
were viable and fertile, Stab2-cre founder 2 (f2) and founder 3 (f3). The founder lines 
were characterised by reporter strains, the R26LacZ 92 (f2;LacZ and f3;LacZ) and the 
R26YFP 93 (f2;YFP and f3;YFP) mouse. The reporter activity was analysed in the fetal and 
adult mouse and results of the founder lines compared. 
 
3.1.1.2. Reporter analysis during fetal development 
3.1.1.2.1. Initiation of liver development 
In order to determine the onset of Cre activity, the Stab2-cre mouse was analysed during 
embryogenesis. F2;LacZ and f3;LacZ embryos were investigated by whole-mount β-
galactosidase assay during initiation of liver development, at E9.5 and at E10.5 (Figure 5). 
Cre expression induces the excision of a stop codon leading to the transcription of the β-
galactosidase protein (LacZ) which reacts with the X-gal substrate (5-bromo-4-chloro-
indolyl-β—D-galactopyranoside) in order to generate an insoluble blue precipitate (5,5’-
dibromo-4,4’-dichloro-indigo) 94. 
 
At E9.5, f2;LacZ embryos showed a LacZ expression in the FL and in the dorsal part of the 
embryo (Figure 5 A). At E10.5, reporter activity of f2;LacZ embryos was observed 
throughout the embryo with signals in the cranial region, dorsal aorta and somites. The FL 
demonstrated a strong LacZ expression (Figure 5 C). Additionally, a reporter signal was 
detected in the YS (not shown). In contrast to this, the f3;LacZ embryos showed neither a 
LacZ signal at E9.5 (Figure 5 B) nor at E10.5 (Figure 5 D). 
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Figure 5: β-galactosidase assay of f2;LacZ and f3;LacZ at E9.5 and E10.5.
A – D, F2;LacZ (A, C) and f3;LacZ (B, D) embryos were dissected at E9.5 (A, B) or E10.5 (C, D), and subjected 
to whole-mount β-galactosidase assay. Embryos were photographed under a stereo microscope. The detail 
in A shows a magnification of the FL of f2;LacZ embryo at E9.5. Representative images from two 
independent experiments with at least three biological replicates. 
 
 
Based on this, the embryos of Stab2-cre f2 were examined more in detail and analysed by 
the R26YFP reporter line. Here, Cre expression leads to the expression of the yellow 
fluorescent protein (YFP), instead of the LacZ protein, which was then detected by direct 
fluorescence or antibody staining. F2;YFP embryos were dissected at E10.5 and analysed 
by immunofluorescence (IF). The cranial region showed distinct CD31+ cells with YFP 
expression (Figure 6 A) whereas in the AGM region multiple YFP+ CD31+ cells were 
detected (Figure 6 B). In the liver, endothelial reporter activity was observed in CD31+ 
cells (Figure 6 C) and in Stab2+ cells (Figure 6 D). The reporter activity was also detected 
in CD31- non-endothelial round cells. In order to analyse if these cells are of 
haematopoietic origin a co-staining with cKit for haematopoietic stem cells (HSC) 95 or 
with Ter119 for immature erythrocytes 95 was performed. YFP expression was observed in 
erythrocyte progenitor cells but not in HSC (Figure 6 E). 
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Figure 6: Immunofluorescent analysis of f2;YFP embryos at E10.5.
A – E, Immunofluorescence (IF) on cryosections of f2;YFP embryos at E10.5. Images from confocal 
microscopy shows YFP (green), endothelial marker CD31 (red), and DAPI (grey) in the cranial region (A), 
AGM region (B), and FL (C). Micrographs of the FL after IF of YFP (green) with Stab2 (red) and CD31 (grey) 
(D) or with Ter119 (red) and cKit (grey) (E). Scale bar 20µm (A - C) and 5µm (D, E). Representative images 
from two independent experiments with two three biological replicates. 
 
3.1.1.2.2. Fetal liver maturation 
Based on the previous results, reporter activity of f2;YFP embryos was investigated later 
during fetal development. During mid-gestation, at E12.5, organs, such as the liver, heart, 
the somites have been formed and intestinal anlagen have been separated into foregut, 
midgut, and hindgut 96. Haematopoiesis shifts from AGM region and extraembryonic tissue 
to the liver 66. YFP expression in f2;YFP embryos was investigated in CD146+ EC of the 
brain, heart, liver, midgut, and somites as well as in LYVE1+ FL EC of f3;YFP embryos 
(Figure 7). Furthermore, reporter activity was analysed in FL cells more in detail (Figure 
8). 
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Figure 7: Immunofluorescent analysis of f2;YFP and f3;YFP embryos at E12.5.and E13.5.  
A – E, IF was carried out on cryosections of f2;YFP embryos at E12.5. Images from confocal microscopy 
shows YFP (green) and CD146 (red) in the brain (A), heart (B), liver (C), midgut (D), and somites (E). F, IF 
was carried out on cryosections of f3;YFP embryos at E13.5. Confocal micrograph shows YFP (green) and 
LYVE1 (red) in the FL. Scale bar 20µm. Representative images from more than three independent 
experiments with at least three biological replicates. 
 
YFP expression was observed in CD146+ EC of the brain (Figure 7 A), midgut (Figure 7 D), 
and somites (Figure 7 E) whereas no YFP was seen in CD146+ EC of the heart (Figure 7 B). 
F3;YFP embryos showed no reporter activity in the FL at E13.5 (Figure 7 F). In the liver of 
f2;YFP embryos (Figure 7 C), YFP expression was observed in two cell types, CD146+ EC 
and in CD146- non-endothelial round cells. A comprehensive analysis of the reporter 
activity in the FL cells demonstrated a YFP expression in Stab2+ LSECs (Figure 8 A) but not 
in Liv2+ immature hepatocytes (Figure 8 B). Interestingly, reporter activity was observed 
in Cre+ cells and in non Cre expressing cells (Figure 8 C) indicating a reporter activity in 
cells without active Cre recombinase. Furthermore, reporter activity was detected in cKit+ 
haematopoietic stem cells (Figure 8 D), in Ter119+ erythroblasts (Figure 8 E), and in 
F4/80+ FL macrophages (Figure 8 F). This prompted us to investigate the YFP reporter 
expression in haematopoietic cells of the FL by fluorescent activated cell sorting (FACS). 
YFP expression was detected in 15.7% of Sca1+ and cKit+ haematopoietic stem cells 
(Figure 8 G) as well as in 5.7% CD45+ CD146- Sca1- cKit- differentiated haematopoietic 
stem cells (Figure 8 H).  
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In summary, the analysis from E9.5 to E13.5 demonstrated a reporter activity in Stab2-cre 
f2 but not in Stab2-cre f3. F2 showed a reporter activity in the FL from E9.5 onwards, in 
the head and AGM region at E10.5 and in the brain, somites, and midgut but not in the 
heart at E12.5. Reporter activity was also observed in liver ECs and in subpopulations of 
haematopoietic stem and differentiated cells. 
 
  
 
Figure 8:  Immunofluorescent analysis of fetal livers of f2;YFP embryos at E12.5 and at E13.25. 
A – F, IF on cryosections of f2;YFP embryos at E12.5. Images from confocal microscopy shows the FL with 
co-staining of YFP (green) and Stab2 (A), Liv2 (B), Cre (C), cKit (D), Ter119 (E), or F4/80 (F). Scale bar 5µm. 
Representative images from more than three independent experiments with at least three biological 
replicates.  G – H, FL cells of f2;YFP embryos at E13.25 were subjected to fluorescent activated cell sorting 
(FACS) and analysed for YFP expression in Sca1+ cKit+ cells (G) and in CD45+ CD146- Sca1- cKit- cells (H). 
Representative FACS plots from one experiment with five biological replicates. 
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3.1.1.3. Reporter analysis in the adult mouse  
3.1.1.3.1. Analysis of liver, bone marrow, lymph node, and spleen 
Next, the reporter activity was analysed in the adult mouse. Liver, tibia and femur, 
mesenteric LNs, and spleen from f2;YFP and f3;YFP mice were harvested and YFP 
expression was investigated.  
 
 
Figure 9:  Immunofluorescent analysis of livers from f2;YFP and f3;YFP mice.
A – J, IF was carried out on liver cryosections of f2;YFP and f3;YFP  mouse followed by confocal microscopy. 
Livers of f2;YFP (A – E) and f3;YFP  (F – J) were stained for YFP (green) and CD32b (red) (A, J), CD31 (red) 
(B, G), Stab2 (red) (C, H), CD68 (red) (D, I), or Desmin (red) (E, J). DAPI (grey) stains the cell nuclei. Scale 
bar 20 µm (A, F) or 5µm. Representative images from more than five independent experiments with more 
than five biological replicates. 
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Livers of the f2;YFP (Figure 9 A - E) and the f3;YFP (Figure 9 F - J) mice showed a YFP 
expression. CD32b+ LSECs of f2;YFP and f3;YFP expressed YFP. F2;YFP demonstrated a 
broader and more intense YFP expression pattern in the liver than f3;YFP (Figure 9 A, F). 
In both founder lines, we observed YFP expression in CD31+ venous and arterial ECs 
(Figure 9 B, G) and in Stab2+ LSECs (Figure 9 C, H). Hepatocytes represent the major cell 
type in the liver but the explicit sinusoidal expression pattern of the reporter excluded a 
hepatocellular reporter activity. Co-staining of YFP with Kupffer cell marker CD68 in livers 
of f2;YFP and f3;YFP (Figure 9 D, I) mice showed the absence of reporter activity in these 
cells.  Stellate cells are resident liver cells in the perisinusoidal space and can be identified 
as Desmin+ cells 97. Due to their close contact with sinusoidal ECs an incidental co-
localisation of Desmin and YFP was observed (Figure 9 E, J) although the signal derived 
from different cells.  
 
In summary, the reporter analysis in the liver showed Cre activity in endothelial sinuses of 
Stab2-cre f2 and f3. F2 displayed a YFP expression in a larger number of LSECs. Both 
founder lines show reporter activity in arterial and venous EC but not in hepatocytes, 
Kupffer or stellate cells.   
 
 
 
Figure 10 (continued on the next page)
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In the BM, YFP expression was detected in f2;YFP (Figure 10 A - C) and f3;YFP (Figure 10 
D - F). CD31+ EC in f2;YFP and f3;YFP and Stab2+ cells in f2;YFP and f3;YFP expressed YFP. 
Furthermore, the BM of f2;YFP showed YFP expression in CD31- and Stab2- cells which 
was not observed in the BM of f3;YFP. This will be analysed more in detail in section 
3.1.1.3.2. Analysis of the LN showed a YFP expression in f2;YFP (Figure 10 G - I) and f3;YFP 
(Figure 10 J - L) . CD31+ EC lining HEVs and trabeculae expressed YFP in LNs of f2;YFP and 
 
Figure 10 (continued): Immunofluorescent analysis of BM, LN, and spleen from f2;YFP and f3;YFP
mice. 
A – R, Cryosections show the BM, mesenteric LNs, and spleen of f2;YFP (A – C, G – I, M – O) and f3;YFP  (D – 
F, J – L, P – R). Organs were subjected to IF of YFP (green) with CD31 (red) or Stab2 (red) in the BM (A - F), 
LN (H – L), and spleen (M – R).  B, E, H, K, N, or Q is a magnification of the selected area in A, D, G, J, M, or P, 
respectively. Scale bar 20 µm (A, D, G, J, M, and P) or 5µm. Representative images from at least three 
independent experiments with more than three biological replicates. 
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f3;YFP. Co-staining with Stab2 demonstrated a YFP expression in Stab2+ cells of f2;YFP and 
f3;YFP. Furthermore, YFP was detected in CD31- and Stab2- cells of the LN of f2;YFP but 
not of the LN of f3;YFP. The spleen demonstrated a reporter activity in f2;YFP (Figure 10 M 
- O) and f3;YFP (Figure 10 P - R). Reporter YFP expression was observed in CD31+ EC and 
Stab2+ cells. Similar to the BM and LN, YFP expression was also seen in CD31- and Stab2- 
splenic cells of f2;YFP but not in f3;YFP. 
 
In summary, Stab2+ microvascular EC of BM, LN, and spleen of f2;YFP and f3;YFP showed 
YFP expression. Both founder lines demonstrated a reporter activity in arterial and venous 
ECs of BM, LN, and spleen. Different observations were made with regard to non-
endothelial reporter activity in the founder lines since f2;YFP showed YFP expression in 
CD31- Stab2- non-EC which was not observed in f3;YFP. 
 
3.1.1.3.2. FACS analysis of the peripheral blood mononuclear cells, bone 
marrow, and spleen 
In previous sections, reporter YFP expression of f2;YFP was detected in non-ECs of BM, LN 
and spleen. Since reporter activity was also observed in FL haematopoietic cells during 
development we applied FACS analysis to characterise the reporter activity in peripheral 
blood mononuclear cells (pBMCs), BM and splenic cells of f2;YFP and f3;YFP more in 
detail. Due to technical difficulties, the LNs were not be examined by FACS analysis. 
Reporter YFP expression was detected in 11.5% of pBMCs in f2;YFP (Figure 11 A) and in 
less than 0.01% (6.2 x 10-3) of pBMCs in f3;YFP (Figure 11 D). Detailed analysis of the 
reporter activity in the blood of f2;YFP showed that 7.7% of b-cells, 6.4% of t-cells, 8.0% of 
granulocytes, and 7.4% of macrophages (Figure 11 B) expressed YFP. In the BM, 3.9% 
YFP+ cells were found in all BM cells of f2;YFP (Figure 11 D) which is in contrast to a YFP 
expression in less than 0.1% (1.6 x 10-2) BM cells of f3;YFP (Figure 11 F). Investigation of 
BM cells from f2;YFP demonstrated that 9.6% of long term (lt)-HSC, 8.1% of short term 
(st)-HSC, and 7.2% of multipotent progenitor cells (MPP) expressed YFP (Figure 11 E). 
Reporter activity was investigated in splenic cells and resulted in a YFP expression in 3.6% 
of total spleen cells in f2;YFP (Figure 11 G) and in 0.1% YFP+ splenic cells in f3;YFP (Figure 
11 I). Splenic cells of f2;YFP were investigated more in detail and showed that 7.3% of b-
cells, 6.1% of t-cells, 6.7% of granulocytes, and 6.7% of macrophages (Figure 11 H) 
expressed YFP.  
 
Results 
30 
 
 
 
In summary, reporter activity was observed in a variable fraction (3% - 12%) of pBMCs, 
BM and spleen of f2;YFP and in less than 0.1% of pBMCs, BM and spleen of f3;YFP.  6% to 
8% of macrophages, granulocytes, b- and t-cells in the blood and spleen as well as 7% to 
10% of lt-HSC, st-HSC and MPP in the BM demonstrated YFP expression.  
  
Figure 11: FACS analysis of pBMCs, BM, and spleen from f2;YFP and f3;YFP mice.
A – I, FACS analysis of YFP expression in the pBMCs, BM, and spleen. YFP expression was analysed in pBMCs 
of f2;YFP (A) and in f3;YFP (C), BM cells of f2;YFP (D) and f3;YFP (F), and splenic cells of f2;YFP (G) and in 
f3;YFP (I).  The percentage of the YFP+ population in FSC/SSC gated pBMCs, BM or splenic cells is illustrated 
by an YFP/SSC FACS plot. YFP expression was analysed in CD19+ CD3- b-cells, CD3+ CD19- t-cells, CD4+ Gr1- 
CD3- CD19- macrophages (Mph), or CD4+ Gr1+ CD3- CD19- granulocytes (Gr) of  the pBMCs (B) or spleen (H) 
as well as was YFP expression analysed in Lineage- Sca1+ cKit+ (LSK) CD48- CD150+ long term (lt)-, LSK 
CD48-C D150- short term (st)-HSC, or LSK CD48- CD150- multipotent progenitor cells (MPP) of the BM of 
f2;YFP (E). Representative FACS plots from one (B, H), two (E), or more than three experiments with at 
least three biological replicates. 
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3.1.1.3.3. Investigation of kidney, pancreas, small intestine, and thymus 
As reporter activity of both founder lines was not strictly confined to Stab2+ 
microvascular EC, the analysis was extended to organs harbouring fenestrated EC. Kidney, 
intestine, pancreas, and thymus of f2;YFP and f3;YFP were harvested and subjected to 
immunofluorescent staining of YFP.  
 
 
Figure 12 (continued on the next page)
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In the kidney, YFP expression was observed in f2;YFP; namely in CD31+ EC lining the 
glomerular capillaries  and the arteries and vein of the renal medulla (Figure 12 A). No 
reporter activity was detected in the kidney of f3;YFP (Figure 12 B). In the intestine of 
f2;YFP, YFP expression was detected in CD31+ EC of the villi (Figure 12 C) whereas no YFP 
expression was observed in the small intestine of f3;YFP (Figure 12 D). In the pancreas of 
f2;YFP, YFP expression was observed in CD31+ EC (Figure 12 E). In some f3;YFP mice (3 of 
8 mice) we detected YFP in CD31+ EC (Figure 12 F). In the thymus of f2;YFP, YFP 
expression was seen in CD31+ EC and in CD31- non-EC (Figure 12 G). FACS analysis was 
carried out in order to examine the YFP+ population more in detail (Figure 12 I). We 
discovered that 5.8% of CD4+ t-cells, 5.8% of CD8+ t-cells, 6.3% of CD4+ CD8+ t-cells, and 
6.6% of CD4- CD8- t-cells expressed YFP. The thymus of f3;YFP showed reporter activity in 
CD31+ EC (Figure 12 H). 
In summary, analysis of the f2;YFP mouse showed reporter activity in ECs of the kidney 
and intestine, whereas f3;YFP did not show a YFP expression in those organs. F2;YFP and 
f3;YFP displayed endothelial reporter activity in the pancreas and thymus, and in addition, 
t-cells expressed the YFP reporter in the thymus of f2;YFP. 
 
  
 
Figure 12 (continued): Immunofluorescent analysis of kidney, small intestine, pancreas and thymus
from f2;YFP and f3;YFP mice. 
A – H, IF was carried out on cryosections from kidney (A, B), small intestine (C, D), pancreas (E, F), and 
thymus (G, H) of the f2;YFP (A, C, E, G) and f3;YFP  (B, D, F, H) mouse. Images from confocal microscopy 
show staining of YFP (green), CD31 (red), and DAPI (grey). Selected areas in A, C, E, F, G, or H are magnified 
in the right image next to it. Scale bar 20 µm or 5 µm (magnification). Representative images from at least 
two independent experiments with more than three biological replicates. I, FACS plots show YFP expression 
in CD4+ CD8- or CD4- CD8+ t-cells as well as in CD4+ CD8+ double positive (DP) or CD4- CD8- double negative 
(DN) t-cells of the f2;YFP mouse. Representative FACS plots from one experiment with five biological 
replicates. 
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3.1.1.3.4. Analysis of aorta, brain, eye, heart, lung, and skin 
Next, we were interested whether aorta, brain, eye, heart, lung, and skin demonstrated 
reporter activity. For this purpose, organs were dissected from f2;YFP and f3;YFP and the 
reporter activity investigated by IF of YFP. 
 
 
Figure 13 (continued on the next page)
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YFP expression was observed in the aorta of f2;YFP (Figure 13 A), namely in CD31+ ECs, 
but not in the aorta of f3;YFP (Figure 13 b). Few CD31+ EC of the cerebral cortex (Figure 13 
C) and most CD31+ EC in the choroid of the eye (Figure 13 E) of f2;YFP expressed YFP. 
Reporter YFP expression was neither observed in the brain (Figure 13 D) nor eye of f3;YFP 
(Figure 13 F). Cardiac CD31+ EC showed a YFP expression in f2;YFP (Figure 13 G) but not 
in f3;YFP (Figure 13 H). In the pulmonary endothelium, a strong reporter YFP expression 
(Figure 13 I) was observed in f2;YFP that was absent in the lung of f3;YFP (Figure 13 J). 
CD31+ EC of the skin in f2;YFP showed a YFP expression (Figure 13 K) that was not 
observed in the skin of f3;YFP (Figure 13 L).  
 
 
3.1.1.4. Summary 
Reporter activity was investigated in two founder lines of the Stab2-cre mouse. Both 
transgenic lines showed Cre activity in LSECs and Stab2+ microvascular ECs of BM, LN, and 
spleen. In f2, YFP expression was detected in haematopoietic cell populations of the FL, 
BM, pBMCs, spleen, and thymus which was not observed in f3. Broad reporter activity of f2 
was detected in vascular beds of most organs whereas the reporter activity of f3 in arterial 
and venous ECs was restricted to the BM, LN, spleen, and thymus. 
  
 
Figure 13 (continued): Immunofluorescent analysis of aorta, cerebral cortex, eye, heart, lung, and 
skin from f2;YFP and f3;YFP mice. 
A – L, IF was carried out on cryosections from aorta (A, B), brain (C, D), eye (E, F), heart (G, H), lung (I, J), 
and skin (K, L) of the f2;YFP (A, C, E, G, I, K) and f3;YFP (B, D, F, H, J, K) mouse. Images from confocal 
microscopy show staining of YFP (green), CD31 (red), and DAPI (grey).  Selected areas in A, C, E, G, I, or K 
are magnified in the right image next to it. Scale bar 20 µm or 5 µm (magnification). Representative images 
from one (A, B) or more than two independent experiments with at least three biological replicates. 
Results 
35 
 
3.1.2. The Clec4g-cre mouse  
3.1.2.1. The generation of the transgenic Clec4g-cre mice 
 
CLEC4G is a member of the lectin family that recognizes a variety of carbohydrate 
structure such as mannose and fucose as ligands on cell surfaces.  The tissue expression of 
murine CLEC4G is largely unknown due to the lack of proper antibodies but function and 
expression pattern of the human Clec4g has been investigated intensively. It is expressed 
by endothelial sinuses of liver and LN and is also found in Kupffer cells. The human 
CLEC4G shares about 65% homology to the murine CLEC4G and both show similar binding 
properties 98–103.  
Since the human CLEC4G protein is widely recognized as a LSEC marker, we generated a 
transgenic Cre mouse whose Cre activity is driven by the murine CLEC4G promoter to 
create an LSEC-specific Cre mouse (Clec4g-cre). After initial screening of three founder 
lines (12.5, f18.3 and f20.1), founder 12.5 (f12.5) was chosen for broad analysis of Cre 
activity with the R26YFP 93 (f12.5;YFP) reporter mouse.  
 
3.1.2.2. Reporter analysis in the liver 
3.1.2.2.1. Mid- and late-gestation of fetal liver development 
In order to determine the onset of Cre activity, embryos from f12.5;YFP were analysed 
during fetal development. Expression of Clec4g mRNA was described in the FL from E15.5 
onwards 104 and timed matings were prepared for f12.5;YFP embryo dissection at E13.5, 
E15.5 and E17.5.  
Reporter activity was detected in the FL at E13.5 (Figure 14 A). Expression of YFP was 
observed in two distinct cell types, in a low number of LYVE1+ EC and in a great majority 
of LYVE1- non-endothelial round cells. Additionally, YFP expression was found in some 
CD68+ FL myeloid cells (Figure 14 B) and in a few cKit+ HSCs (Figure 14 C). At E15.5, 
similar YFP expression pattern was seen in the FL, namely in LYVE1+ ECs and LYVE1- 
round cells, but we observed a broader endothelial reporter YFP expression than at E13.5 
(Figure 14 D). Reporter expression was also found in CD68+ FL myeloid cells (Figure 14 E). 
The FL at E17.5 showed reporter YFP expression predominantly in LYVE1+ EC and almost 
no YFP+ LYVE1- round cells were detected in the FL (Figure 14 F). Besides this, CD31+ FL 
arterial and venous EC displayed reporter YFP expression (Figure 14 G). 
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Figure 14: Immunofluorescent analysis of f12.5;YFP embryos at E13.5, E15.5, 17.5. 
A - G, IF was carried out on cryosections from f12.5;YFP embryos at E13.5 (A) and at E15.5 (B) or on 
dissected livers from f12.5;YFP embryos at E17.5 (C). Images from confocal microscopy show the FL with 
co-staining of YFP (green), DAPI (grey) and LYVE1 (red) (A, D, F), CD68 (red) and LYVE1 (blue) (B, E, G), or 
cKit (red) (C). Scale bar 20 µm (A, D, F) or 5 µm. Representative images from two experiments with at least 
two biological replicates. 
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3.1.2.2.2. Immunofluorescent staining of the adult liver  
In order to analyse the suitability of the Clec4g-cre mouse to target LSECs, reporter 
activity of f12.5;YFP was analysed in the adult mouse. Livers of were harvested and 
subjected to immunofluorescent analysis. 
 
Figure 15: Immunofluorescent analysis of livers from f12.5;YFP mouse. 
A - E, Liver cryosections of the f12.5;YFP mouse were subjected to IF and analysed by confocal microscopy. 
Micrographs show staining of YFP (green), DAPI (grey) and CD32b (red) (A), CD31 (red) (B), Stab2 (red) 
(C), CD68 (red) (D), or Desmin (red) (E). Scale bar 20 µm (A) or 5 µm. Representative images from at least 
three experiments with more than five biological replicates. 
 
The liver of f12.5;YFP displayed a YFP expression with a strong sinusoidal expression 
pattern (Figure 15). YFP was detected in CD32b+ and Stab2+ microvascular ECs (Figure 15 
A, C) as well as in CD31+ ECs lining the CV and portal vessels (Figure 15 B). In order to 
differentiate the YFP staining of ECs lining the sinusoids from Kupffer cells and stellate 
cells, co-staining of YFP with CD68 and Desmin were carried out. Neither CD68+ Kupffer 
cells (Figure 15 D) nor Desmin+ stellate cells (Figure 15 E) demonstrated reporter activity.  
 
In summary, reporter activity was observed in the liver of the f12.5;YFP mouse from E13.5 
onwards. The number of YFP+ liver ECs was low during mid-gestation and increases then 
until in the adult liver all Stab2+ and CD32b+ LSECs as well as CD31+ EC showed reporter 
YFP expression. During fetal development a fraction of haematopoietic cells displayed 
reporter activity.  
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3.1.2.3. Reporter analysis in non-hepatic organs  
3.1.2.3.1. Investigation of peripheral blood mononuclear cells, bone marrow, 
lymph node, and spleen 
Next, reporter activity was analysed in other Stab2+ microvascular beds. BM, LN and 
spleen were dissected from f12.5;YFP mice and YFP expression examined by IF. 
 
 
Figure 16: Immunofluorescent analysis of BM, LN, and spleen from f12.5;YFP mouse.  
A – F, Cryosections show the BM (A, B), mesenteric LNs (C, D), and spleen (E, F) of the f12.5;YFP mouse. 
Images from confocal microscopy after IF show YFP (green) with CD31 (red) or Stab2 (red). Selected areas 
in A, C, or E are magnified in the right image next to it. Scale bar 20 µm or 5 µm (magnification, B, D, F). 
Representative images from at least two independent experiments with more than three biological 
replicates. 
 
Reporter YFP expression was observed in the BM (Figure 16 A, B), LN (Figure 16 C, D) and 
spleen (Figure 16 E, F) of the f12.5;YFP mouse. In the BM, reporter YFP expression was 
neither observed in CD31+ EC (Figure 16 A) nor in Stab2+ cells (Figure 16 B). In the LN, 
CD31+ EC lining the blood vessel but not the HEV (Figure 16 C) displayed YFP expression. 
YFP was also observed in Stab2+ cells (Figure 16 D). In the spleen, YFP expression was 
neither detected in CD31+ EC (Figure 16 E) nor in Stab2+ cells (Figure 16 F). 
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In order to characterise the YFP+ but CD31- Stab2- cell population more in detail, FACS 
analyses were performed. Cells from pBMCs, BM and spleen were harvested and analysed 
for reporter activity in haematopoietic cells.  
 
 
Figure 17: F12.5;YFP shows reporter activity in haematopoietic cells of the pBMCs, BM, and spleen.
A – I, YFP expression was analysed by FACS in pBMCs (A - B), the BM (C - E) or spleen (F - I) from 12.5;YFP. 
The percentage of the YFP+ population in FSC/SSC gated pBMCs (A), BM (C) or splenic cells (F) is illustrated 
by an YFP/SSC FACS plot. YFP+ cells were then gated for CD11b and CD11c (B, H), CD45 and Ly6C/Ly5G 
(Gr-1) (D), CD45 and CD11b (E), or CD11b and F4/80 (I) expression. The cell number of the respective 
population is illustrated in relation to the total cell number of YFP-expressing cells. YFP+ splenic cells were 
gated for CD19 expression (G) and the number of CD19+ cells is depicted in relation to the total cell number 
of YFP+ cells in the FACS plot. Representative FACS plots of two independent experiments with more four 
biological replicates. 
 
YFP expression was detected in 1.1% of pBMCs (Figure 17 A). Cells were gated for YFP+ 
and analysed for reporter activity in CD11b+ CD11c+ monocytes, CD11b+ CD11b- 
macrophages and CD11b- CD11c+ dendritic cells 105,106. 4.3% were CD11b- CD11c+ cells, 
19.7% were CD11b+ CD11c+ cells and 36.5% were CD11b+ CD11c- cells. In the BM, 2.0% of 
cells expressed YFP (Figure 17 B). The YFP+ cells were identified and gated by CD45 and 
CD11b expression in order to identify CD45+ CD11b- immature monocytes  and CD45+ 
CD11b+ neutrophils and macrophages 107 as well as by CD45 and Gr-1 expression to 
identify CD45+ Gr-1low monocytes and CD45+ Gr-1high neutrophils 108. 40.5% were CD45+ 
CD11b+, 40.2% were CD45+ CD11b- and 0.8% were CD45- CD11b+ as well as 42.4% were 
CD45+ Gr-1+, 36.2% were CD45+ Gr-1- and 3.0% were CD45- Gr-1+ cells. In the spleen, 
reporter YFP expression was detected in 1.0% of the total splenic cells (Figure 17 C). The 
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YFP+ cells were gated by the expression of CD19 to identify b-cells 109 and showed that 
19.3% of YFP+ cells were also CD19+ b-cells. Additionally, cells were gated for YFP-
positivity and CD11b and CD11c splenic dendritic cells or CD11b and F4/80 splenic 
macrophages were identified 110,111. A fraction of the YFP+ cells were CD11b- CD11c+ 
(12.1%), CD11b+ CD11c+ (12.3%), CD11b+ CD11c- (9.8%) cells or CD11b- F4/80+ (1.0%), 
CD11b+ F4/80+ (4.1%), CD11b+ F4/80- (26.1%) cells. 
 
Taken together, the f12.5;YFP mouse showed reporter activity in Stab2+ microvascular 
and CD31+ EC in the LN. FACS analysis demonstrated that only a small percentage of the 
cells in the pBMCs, BM and spleen expressed YFP. Of those cells a variable fraction of 
monocytes and myeloid cells as well as splenocytes displayed YFP expression.  
 
3.1.2.3.2.  Analysis of the intestine, kidney, pancreas, and thymus 
F12.5;YFP mice were investigated in the intestine, kidney, pancreas, and thymus to 
provide a comprehensive analysis. Organs were collected and YFP expression investigated 
by IF. 
 
 
Figure 18 (continued on the next page)
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Figure 18 (continued): Immunofluorescent analysis of kidney, small intestine, pancreas, and thymus
from f12.5;YFP mouse. 
A – G, IF was carried out on cryosections of kidney (A), intestine (B, C), pancreas (D, E), and thymus (F, G). 
Images from confocal microscopy show YFP (green), DAPI (grey) with CD31 (red) (A, B, D, F), CD68 (red) 
and CD11b (blue) (C, E), or CD3 (red) (G). Selected areas in A, B, D or F are magnified in the right image 
next to it. Scale bar 20 µm or 5 µm (magnification, C, E, and G). Representative images from at least three 
independent experiments with more than three biological replicates. 
 
Reporter activity was detected in a few cells of the kidney (Figure 18 A) that were 
identified as CD31- cells. In the small intestine, YFP expression was observed in distinct 
CD31- cells of the villi (Figure 18 B). CD68 and CD11b were reported to stain different sub-
types of myeloid cells of the intestinal mucosa 112,113. Co-staining of YFP with CD68 and 
CD11b revealed a reporter activity in intestinal macrophages and intestinal dendritic cells 
of the f12.5;YFP mouse, respectively (Figure 18 C). In the pancreas, few YFP+ cells were 
observed (Figure 18 D). These cells were CD31- non-EC and co-expressed CD68 and CD11b 
(Figure 18 E) demonstrating a reporter activity in pancreatic myeloid cells. In the thymus, 
YFP expression was detected in CD31- non-ECs (Figure 18 F) which were defined as CD3+  
t-cells expressing YFP (Figure 18 G).  
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3.1.2.3.3. Characterisation of the brain, heart, lung, and skin 
Next, reporter activity was investigated in EC lining the vascular beds of brain, heart, lung, 
and skin. Organs were harvested from the f12.5;YFP mice and expression of YFP was 
analysed. 
 
 
Figure 19: Immunofluorescent analysis of brain, heart, lung, and skin from f12.5;YFP mouse. 
A – F, IF was carried out on cryosections of brain (A), heart (B), lung (C, D), and skin (E, F). Images from 
confocal microscopy show YFP (green), DAPI (grey) and CD31 (red) (A, B, C, E), CD11b (red) and LYVE1 
(blue) (D), or CD11b (red) (F). Selected areas in A, B, C, or E are magnified in the right image next to it. Scale 
bar 20 µm or 5 µm (magnification, D, F). Representative images from at least two independent experiments 
with at least three biological replicates. 
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The brain of the f12.5;YFP mouse showed reporter activity in CD31- non-ECs of the pre-
frontal cortex (Figure 19 A), no YFP expression was detected in other cerebral regions 
such as the hippocampus or cerebellum. In the heart, broad reporter YFP expression was 
observed in CD31+ EC of the myocardium and endocardium (Figure 19 B). Reporter 
activity was detected in the lung but neither was it observed in CD31+ EC (Figure 19 C) nor 
in LYVE1+ lymphatic endothelium. CD11b+ cells of the lung were reported as alveolar 
dendritic cells 114 and co-staining of YFP with CD11b in the lung demonstrated a reporter 
activity in those cells (Figure 19 D). Similar to the lung, the skin of the f12.5;YFP mouse did 
not show reporter YFP expression in CD31+ EC  (Figure 19 E) but in CD11b+ dermal cells 
(Figure 19 F). 
 
3.1.2.4. Summary 
Reporter activity was investigated in the Clec4g-cre mouse model. In the adult liver, YFP 
expression was observed in ECs lining the sinusoids and the vascular bed of the periportal 
and pericentral vessel. In the LN, endothelial reporter activity was detected in the sinuses 
whereas the HEV did not show a YFP expression. Furthermore, endothelial reporter 
activity was only found in the heart. The Clec4g-cre mouse displayed reporter activity in a 
small percentage of haematopoietic cells in BM, pBMCs, intestine, kidney, pancreas, and 
spleen as well as in t-cells. Analysis of the liver during embryonic development revealed 
strong endothelial reporter YFP expression from E15.5 onwards, at earlier time points 
transient reporter activity was also observed in CD68+ haematopoietic cells.   
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3.2. Differentiation of liver sinusoidal endothelial cells 
3.2.1. Function of GATA4 during LSEC development 
Transcriptional regulators that control maturation and differentiation of organotypic 
microvascular EC have not been established. The LSEC-specific differentiation programme 
was investigated by gene expression profiling 24 and identified GATA4 in a set of TFs by 
comparing rat LSEC with rat lung microvascular EC. During embryogenesis GATA4 is one 
of the earliest TFs expressed in cardiac progenitor cells 75 but study of the molecular 
function in LSECs was compromised by the early embryonic lethality resulting from 
cardiac defects from the general 75,76 and pan-endothelial knockout 77. In order to 
investigate the function of GATA4 in LSECs a Cre driver mouse was required that would 
induce GATA4 deficiency in microvascular EC of the liver but not in ECs of the developing 
heart.  
Screening of the LSEC-Cre driver mouse lines demonstrated Cre activity of Stab2-cre f2 in 
fetal LSEC but not in the fetal heart (Figure 5 - Figure 8). Stab2-cre f3 did not show 
reporter activity during fetal development (Figure 7). Endothelial reporter activity in 
livers of Clec4g-cre embryos was observed from E15.5 onwards (Figure 14), however, 
endothelial YFP expression was not as strong as for Stab2-cre f2. Therefore, Stab2-cre f2 
was examined for suitability to generate GATA4 specific knockout in fetal LSECs.  
 
3.2.1.1. Stab2-cre driven GATA4 deficiency in the fetal liver endothelium  
Double immunofluorescent labelling of GATA4 with Stab2 showed a co-expression in the 
FL (Figure 20 A) but not in the fetal heart (Figure 20 C). This is in contrast to CD31 and 
GATA4 double labelling in hepatic (Figure 20 B) and cardiac ECs (Figure 20 D) suggesting 
the Stab2 promotor driven Stab2-cre mouse as a suitable Cre driver. Besides the reporter 
activity of the f2;YFP mouse in fetal (Figure 6 D, Figure 8 A) and adult LSECs (Figure 9 A, 
C), co-expression of the reporter with GATA4 was observed in ECs of the FL (Figure 20 E). 
This established Stab2-cre f2 as an ideal Cre driver mouse to study GATA4 function in 
LSECs. 
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Figure 20: Stab2-cre f2 mouse is suitable to analyse GATA4 function in LSECs during fetal 
development. 
A – D, IF was carried out on cryosections of wildtype embryos at E10.5. Images from confocal microscopy 
show the FL or the fetal heart with co-staining of GATA4 (red) with Stab2 (green) or CD31 (green). E, IF was 
carried out on cryosections of f2;YFP embryos at E12.5. Single channel images and composite image after 
confocal microscopy show the FL with co-staining of YFP (green) and GATA4 (red). Scale bar 5 µm. 
Representative images from at least two independent experiments with more than three biological 
replicates. 
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3.2.1.2. Basic analysis 
3.2.1.2.1. Stab2-cre driven GATA4 deficiency causes embryonic lethality 
Mice homozygous for the Gata4loxP allele were bred with Stab2-cre f2 mouse to generate a 
heterozygous GATA4 knockout which was then again mated with homozygous Gata4loxP 
mouse to receive a homozygous GATA4 knockout (Gata4∆LSEC) (Figure 21 A). 
 
 
Figure 21: Embryonic lethality of Gata4∆LSEC knockout. 
A, Scheme to illustrate the generation of Gata4∆LSEC or Gata4∆LSEC;YFP knockout mouse. B, Results from 
genotyping of Gata4∆LSEC knockout and control embryos at indicated time points. Viable embryos were 
identified by beating heart. *, at E17.5, two knockout embryos were found in the uterus but did not show a 
heartbeat and had a pale appearance. C – E, Macroscopic images of control (left) and Gata4∆LSEC (right) 
knockout embryos at E10.5 (C), E11.5 (D), and E13.5 (E). Representative images from at least three 
independent experiments with more than three biological replicates. 
 
Distribution of the genotypes showed a normal Mendelian ratio from E9.5 to E14.5 (Figure 
21 B). At E17.5, no viable knockout embryos were found. No knockout was detected 
among the pubs of 4 weeks of age indicating an embryonic lethality between E14.5 and 
E17.5. Knockout embryos were analysed macroscopically (Figure 21 C - E), no differences 
were observed between control and knockout embryos at E10.5. At E11.5 and E13.5 
growth of knockout and control embryos was unaltered but FL was heavily reduced in 
size.  
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3.2.1.2.2. GATA4 knockout in LSEC causes fetal liver growth arrest 
Next, Gata4∆LSEC and control embryos were investigated more in detail by haematoxylin & 
eosin (H&E) staining and the fetal liver and heart were dissected for gross comparison. 
 
Figure 22: Reduced size and distorted structure of livers from Gata4∆LSEC knockout embryos.  
A – D, Photomicrographs of the FL and fetal heart of control (A, B) and Gata4∆LSEC knockout (C, D) embryos 
at E13.5. E – P, H&E staining of control (E, G, I, K, M, O) and Gata4∆LSEC knockout (F, H, J, L, N, P) embryos at 
E13.5. Red dotted lines indicate the FL in the cross-section of the embryos (E, F). H&E staining of the liver 
(G, H) brain (I, J), heart (K, L), lung (M, N), and kidney (O, P). Scale bar 20 µm. Representative images from 
one experiment with at least two replicates. 
 
The dissected FL from Gata4∆LSEC embryos displayed a reduced size compared to control 
embryos (Figure 22 A, C) whereas the heart did not show any gross abnormalities (Figure 
22 B, D). H&E staining showed a severely hypoplastic liver (Figure 22 E, F), an impaired 
vascular organisation and an increase of red blood cells in the knockout liver (Figure 22 G, 
H). Growth and development of vascular structures in brain, lung, and kidney were not 
affected in Gata4∆LSEC embryos (Figure 22 I - P).  
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Figure 23: Immunofluorescent analysis of GATA4 in liver and heart from Gata4∆LSEC knockout and 
control embryos 
A – D, IF was carried out on cryosections of control (A, B) and Gata4∆LSEC knockout (C, D) embryos at E10.5. 
Images from confocal microscopy show the co-staining of GATA4 (red) with Stab2 (green) or CD31 (green) 
in the FL (A, C) or the fetal heart (B, D).  E – F, IF was carried out on cryosections of control (E) and 
Gata4∆LSEC knockout (F) embryos at E11.5. Images from confocal microscopy show the co-staining of CD31 
and LYVE1 (both in green) and GATA4 (red) in the FL. Scale bar 10 µm.  G, Quantification of GATA4+ nuclei 
in CD31+ and LYVE1+ vessels. Scale bar 10 µm. Representative images from at least one experiment with at 
least three replicates. Student’s t test: ***, p < 0.001. 
 
GATA4 deficiency was then assessed by immunofluorescent staining of liver and heart at 
E10.5 (Figure 23 A - D) and E11.5 (Figure 23 E - G). Stab2+ GATA4+ LSECs were not 
observed in livers of Gata4∆LSEC embryos (Figure 23 C) only in livers of control embryos 
(Figure 23 A). GATA4 expression in cardiac EC was not affected in control or in Gata4∆LSEC 
mutant embryos (Figure 23 B, D). The number of GATA4+ nuclei in the liver vasculature 
was quantified using double labelling of the hepatic EC by LYVE1 and CD31 (Figure 23 E - 
G). GATA4+ nuclei were significantly reduced and showed GATA4 expression in less than 
10% of liver EC in the Gata4∆LSEC embryos. This shows the efficient reduction of GATA4 
protein expression in the hepatic microvasculature by the Stab2-cre f2 mouse.  
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3.2.1.3. Investigation of the fetal liver endothelium 
3.2.1.3.1. Characteristics of the GATA4-deficient fetal liver micro-vasculature  
As Gata4∆LSEC embryos displayed a reduced liver size and distorted hepatic vasculature, 
LSEC markers were investigated that characterise the adult liver sinusoids. 
 
 
Figure 24 (continued on the next page) 
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Figure 24 (continued): GATA4 expression in LSECs controls sinusoidal and continuous marker 
expression.   
A – F, Immunohistochemistry was carried out on cryosections of control (A - C) and Gata4∆LSEC knockout (D 
- F) embryos at E11.5 to visualize LYVE1 (A, D), Stab2 (B, E), and CD31 (C, F) expression in the FL. G – I, 
Quantification of LYVE1 (G), Stab2 (H), or CD31 (I) staining in the FL of Gata4∆LSEC embryos at E11.5. IF was 
carried out on cryosections of Gata4∆LSEC embryos at E11.5 and the fluorescent area was quantified in 
relation to the total FL size. J - K, Western Blot and quantification shows expression of LYVE1 in the FL of 
control and Gata4∆LSEC knockout embryos at E11.5. Protein lysates of FL were separated by SDS-PAGE, 
blotted and incubated with antibodies detecting LYVE1 and Gapdh protein (J). Densitometric analysis and 
graphic illustration from Western Blot results (K). L – N, FLs of control (N) and Gata4∆LSEC knockout (M, N) 
embryos at E11.25 were subjected to electron microscopic analysis. O – P, Sirius Red staining of control (O) 
and Gata4∆LSEC knockout (P) embryos shows the FL at E13.5. Scale bar 100 µm (A - F) and 10 µm (O, P). 
Representative images one (L – N) or more than two experiments with at least three replicates. Student’s t 
test: ***, p < 0.001. 
 
 
LYVE1 and Stab2, both expressed by adult LSECs and in control FLs (Figure 24 A, B), 
showed a decreased expression in the FL of Gata4∆LSEC embryos at E11.5 (Figure 24 D, E). 
On the contrary CD31, which is low expressed by adult LSECs and in control FLs (Figure 
24 C), displayed an increased expression in the FL of Gata4∆LSEC embryos at E11.5 (Figure 
24 F). The difference in protein expression of control and Gata4∆LSEC mutant FLs was 
quantified using immunofluorescent micrographs and calculated as fluorescent area in 
relation to hepatic area. The percentage of LYVE1+ fluorescent area was reduced from 
9.6% to 2.0% (Figure 24 G), the percentage of Stab2+ fluorescent area was reduced from 
0.8% to 0.1% (Figure 24 H), and the percentage of CD31+ fluorescent area was increased 
from 1.5% to 5.4% (Figure 24 I). In addition, FL lysates were assessed for LYVE1 protein 
expression (Figure 24 J). We detected a significant lower protein amount of LYVE1 in 
Gata4∆LSEC FL at E11.5 (1.8% vs. 0.3%) (Figure 24 K) indicating a shift from sinusoidal to 
continuous endothelial marker expression in Gata4∆LSEC mutant livers. Sirius Red staining 
visualises collagen fibres and showed a deposition of collagenous proteins in the 
extracellular space in Gata4∆LSEC FLs at E13.5 (Figure 24 P) which was not observed in the 
control FLs (Figure 24 O). Since these changes were very profound, Gata4∆LSEC mutant 
livers were analysed on an ultrastructural level. Electron microscopy showed a formation 
of basement membrane (Figure 24 M) and deposition of ECM (Figure 24 N) in the FL of 
Gata4∆LSEC embryos at E11.5 which was not observed in the FL of control embryos (Figure 
24 L).  
 
In summary, the FL of Gata4∆LSEC transgenic embryos lost the special characteristics of 
liver sinusoidal endothelium. The switch of endothelial marker expression, the increase of 
ECM and formation of a basement membrane were striking in the Gata4∆LSEC mutant 
embryos and can be described as capillarization of the FL endothelium 115,116.  
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Figure 25: GATA4 deficient hepatic endothelium undergoes dedifferentiation.
A – D, IF was carried out on cryosections of control (A, C) and Gata4∆LSEC;YFP knockout (B, D) embryos at 
E11.5. Images from confocal microscopy show the FL with single channels and composite image after IF of 
YFP (green) with CD31 (red) (A, B) or Stab2 (red) (C, D). Scale bar 5 µm. Representative images two 
experiments with at least three replicates. 
 
In order to confirm that the capillarized endothelium results from transdifferentiation of 
the GATA4 deficient transgenic EC rather than from angiogenic processes of Stab2- EC 
without Cre activity, we generated a YFP reporter Gata4∆LSEC mouse (Figure 21 A: 
Gata4∆LSEC;YFP). This mouse model showed YFP expression and GATA4 deficiency upon 
Cre mediated recombination and allowed for visualisation of recombined ECs. In the FL of 
control embryos at E11.5 (here: GATA4 heterozygous deficiency) the YFP+ transgenic ECs 
showed a low CD31 expression (Figure 25 A) whereas in GATA4 homozygous deficient 
embryos the YFP+ transgenic endothelium was characterized by high CD31 expression 
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(Figure 25 B). Furthermore, the YFP+ transgenic endothelium in control livers showed a 
high Stab2 expression (Figure 25 C) in contrast to the YFP+ transgenic EC in Gata4∆LSEC 
livers in which Stab2 expression is almost absent (Figure 25 D). This demonstrated that 
the Stab2-cre driven GATA4 deficiency resulted in a capillarization of the transgenic 
microvasculature.  
 
3.2.1.4. Examination of the fetal liver haematopoiesis 
3.2.1.4.1. Haematopoietic defects upon GATA4 deficiency in fetal LSECs 
So far, Gata4∆LSEC embryos displayed a reduced FL size with an increase of ECM. The 
GATA4 transgenic hepatic endothelium started to transdifferentiate which means loss of 
LSEC marker expression and formation of a basement membrane. Unlike adulthood, the FL 
is essential for seeding and differentiation of haematopoietic stem and progenitor cells. In 
order to evaluate potential defects on haematopoietic events due to hepatic 
maldevelopment, HPCs were quantified at E11.25 as well as the number of HSC was 
investigated at E13.25. 
 
 
Figure 26: Defective haematopoiesis in the Gata4∆LSEC embryos. 
A – B, FACS plot (A) and quantification (B) of CD45lo Kit+ and CD45+ Kit+/- HPCs in the liver, blood and yolk 
sac (YS) of Gata4∆LSEC embryos at E11.25 [liver: n = 14 mutants and 10 controls; blood: n = 15 mutants and 
10 controls; YS: n = 8 mutants and 16 controls (YS controls: Stab2-cretg/wt;Gata4fl/wt, Stab2-crewt/wt;Gata4fl/fl, 
Stab2-crewt/wt;Gata4fl/wt)]. C – D, FACS plots (C) and quantification (D) of LT-HSC, ST-HSC, and MPP in liver 
and blood of Gata4∆LSEC embryos at E13.25. LT-HSC (LSK CD150+ CD48-), ST-HSC (LSK CD150- CD48-) and 
MPP (LSK CD150- CD48+) (liver: n = 8; peripheral blood: n = 7 mutants and 8 controls). Representative FACS 
plots from at two independent experiments with more than five biological replicates. Student’s t test: *p < 
0.05; ***p < 0.001. 
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FL cells of Gata4∆LSEC embryos and littermate controls were isolated at E11.25 and single 
cell suspensions were examined by FACS (Figure 26 A, B).  FACS blots of erythroid myeloid 
progenitor (EMP) marker CD45 and cKit showed a reduction of CD45lo cKit+ and CD45+ 
cKit+/- populations in the FL of Gata4∆LSEC embryos (Figure 26 A). Quantification of total 
cell numbers of CD45lo cKit+ and CD45+ cKit+/- cells confirmed a significant reduction in the 
FL of Gata4∆LSEC embryos in contrast to the increase of total cell numbers of EMPs in the 
peripheral blood of Gata4∆LSEC embryos (Figure 26 B). In the YS of Gata4∆LSEC embryos, the 
total cell numbers of CD45lo cKit+ cells were increased whereas the cell numbers of CD45+ 
cKit+/- cells did not show any differences (Figure 26 B). Next, liver cells of Gata4∆LSEC 
embryos and littermate controls were isolated at E13.25 and analysed by FACS for 
indicated HSC populations (Figure 26 C, D). FACS blots of Lineage- Sca-1+ cKit+ (LSK) stem 
cells, lt-HSC and st-HSC as well as of MPP showed a reduction in the FL of Gata4∆LSEC 
embryos (Figure 26 C). Quantification of the total cell number of lt-HSC, st-HSC and MPP 
revealed a significant decrease in the FL of Gata4∆LSEC embryos and a significant increase in 
the peripheral blood of Gata4∆LSEC embryos (Figure 26 D). 
Thus, at E11.25 and E13.25, the FL of Gata4∆LSEC embryos displayed a strong reduction of 
HSPCs that were vice versa increased in the peripheral blood of Gata4∆LSEC embryos. 
 
3.2.1.4.2. Transplantation of fetal liver HSCs 
The reporter activity of the Stab2-cre f2 mouse in haematopoietic cells at E12.5 and 
E13.25 (section 3.1.1.2) as well as the low number of HSPCs in the FL of Gata4∆LSEC 
embryos at E11.25 and E13.25 (section 3.2.1.4.1) prompted us to investigate the 
multilineage differentiation potential from Gata4∆LSEC embryos. 
 
FL donor cells of E13.25 Gata4∆LSEC embryos and littermate controls were harvested, 
sorted by FACS for LSK+ cells and transplanted into Rag2-/-γc-/-KitW/Wv recipient mice 117 
(Figure 27 A, B). Blood was collected from recipient mice after 4, 10 and 15 weeks and 
analysed for b-cells, t-cells and granulocytes. After 15 weeks, recipient blood from 
Gata4∆LSEC and control donor fetal cells showed formation of b-cells, t-cells and 
granulocytes (Figure 27 C) indicating proper lineage differentiation potential of FL 
haematopoietic cells from Gata4∆LSEC embryos.  
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Figure 27: Analyses of lineage potential of fetal liver haematopoietic cells from Gata4∆LSEC embryos.
A – C, Transplantation of isolated LSK cells from control and Gata4∆LSEC knockout embryos into adult 
immunodeficient mice. Schematic summary of the analysis: FACS sorting of FL donor LSK cells from 
Gata4∆LSEC (n = 3) or control (n = 5) embryos at E13.25. Cells were injected into Rag2-/-γc-/-KitW/Wv mice and 
peripheral blood was analysed for donor-derived lymphoid (CD3+ t-cells, CD19+ b-cells) and myeloid 
(CD11b+ Gr1+ granulocytes) cells after 4, 10, and 15 weeks (A). FACS blots of donor FL cells are shown from 
control and Gata4∆LSEC embryos (B) as well as FACS blots of peripheral blood analysis of the corresponding 
recipient mouse (C). 
 
 
3.2.1.5. Summary 
Function of GATA4 for LSEC formation and development was investigated. The Stab2-cre 
f2 mouse was a suitable Cre driver line due to the Cre activity in fetal LSECs but not in fetal 
cardiac EC. The Stab2-cre driven GATA4 knockout caused an embryonic lethality and a 
severe liver hypoplasia. The defects of the knockout embryos were completely restricted 
to the FL, other developing organs, such as the heart did not show any malformations. 
Livers of the knockout embryos were characterised by a distorted vascular organisation, a 
switch from sinusoidal to continuous endothelial marker expression and a formation of a 
basement membrane. Moreover, we observed an increased expression of VE-Cadherin and 
Laminin α-4 in the GATA4 deficient FL endothelium 118. Transcriptome profiling of the FL 
of Gata4∆LSEC and control embryos demonstrated that loss of GATA4 induced transcription 
of continuous EC-associated genes and that GATA4 protein expression promotes an LSEC-
associated gene expression 118. Finally, Gata4∆LSEC embryos showed severe haematopoietic 
defects which were most likely caused by migratory defects due to proper multilineage 
differentiation potential of the HSC from Gata4∆LSEC FLs. 
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4. Discussion 
4.1. Genetic manipulation of liver sinusoidal endothelial cells in 
vivo 
LSECs form the microvascular bed of the liver and secrete angiocrine factors that are 
critical for organ regeneration and hepatic homeostasis. The unique phenotype is 
represented by the lack of a continuous basement membrane and the presence of open 
pores. However, the investigation of LSEC specific characteristics in vitro is complicated 
due to their dedifferentiation in culture. Analysis of LSEC function in vivo by genetic 
knockout models is often compromised by an early embryonic lethality 119 or function of 
the protein of interest in other tissues and organs 120 and thereby preventing an LSEC 
specific investigation. Therefore, transgenic mouse models were generated that allow for a 
conditional genetic inactivation in the target cell type. 
Targeted knockouts can be facilitated by the Cre/loxP system or the Tet-off/on system 
121,122. The Cre/loxP system utilises the bacteriophage derived protein Cre to fuse, invert or 
excise specific DNA fragments depending on the orientation of the loxP sites 56,123. 
Promoter elements of interest can control the activity of cre in the desired cell type and 
further advances were achieved by fusing cre with sequences encoding a modified form of 
the oestrogen receptor ligand-binding domain (ERT2) to control Cre expression by 
tamoxifen administration 124,125.  
 
4.1.1. Endothelial-specific transgenic Cre driver lines 
Due to the lack of LSEC specific mouse models, transgenic mouse lines with Cre activity in 
ECs in general have been applied. A spectrum of different mouse models has been 
described so far (Table 1). Promoter elements of proteins with an endothelial expression 
drive the Cre recombinase and induce Cre activity in a wide array of the vascular beds. The 
Cdh5, Kdr and Tek genes were used by multiple investigators to generate transgenic mouse 
lines and investigate LSEC specific function of the proteins of interest.  
The Cdh5 gene encodes VE-Cadherin, a component of adherens junctions that is expressed 
in the endothelium of adult mice and during vascular development 126. The Cdh5-cre 
mouse lines were generated by Alva et al. 10 and Chen et al. 11 through fusion a 2.5 kb 
promoter sequence of the Cdh5 gene with the cre gene. Alva et al. observed a reporter 
activity in the FL at E14.5 and in the venous and sinusoidal vessels of the adult liver 58. 
Conditional deletion of the chromodomain helicase DNA-binding 4 protein 127 or the 
Notch1 intracellular domain 128 in LSECs resulted in an embryonic lethality due to an off-
target recombination in lymphatic cells or haematopoietic cells, respectively. Chen et al. 
described a β-gal reporter activity in the FL at E10.5 and in almost all FL haematopoietic 
cells at E15.5 129 which led the majority of researches to use this mouse line for 
investigation of protein function in HSCs of the fetal and adult mice 130–135,129 rather than in 
ECs 136–139.  
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Table 1: Published mouse lines for conditional genetic inactivation in EC 
Driver gene Mouse line Cre activity 
Acvrl1 
Tg(Alk1-cre)-B1 Pan-endothelial at E10.5 and in the newborn mouse 140,141 
Tg(Alk1-cre)-L1 Pulmonary EC and mosaic pattern in other ECs in the newborn mouse 141 
Cdh5 
Tg(Cdh5-cre)7Mlia 
Starting at 7.5, in ECs of the macro- and 
microvasculature, also in lymphatic ECs and 
in the adult quiescent vasculature 58 
Tg(Cdh5-cre)1Spe  Embryonic vasculature and haematopoietic cells 129 
Kdr 
Tg(Kdr-
cre)15962Brei 
EC of all vascular beds in the embryo 59 
Kdrtm1(cre)Sato  Muscle, endothelial and haematopoietic cells 142 
Pecam1 Tg(Pecam-cre)1Roml Ubiquitous active 143 
Tek 
Tg(Tek-
cre)2352Rwng 
ECs and blood cells from E11.5 onwards 144 
Tg(Tek-cre)1Xyfu EC of brain, heart and liver as well as in BM cells and splenocytes 145 
Tg(Tek-cre)1Ywa Pan-endothelial 57 
Tg(Tek-cre)12Flv ECs of brain, kidney, LNs, spleen, and thymus 146 
Tg(Tek-cre)5326Sato Pan-endothelial 147 
Tg(Tek-cre)1Arnd Pan-endothelial, haematopoietic cells 148 
Tg(Tek-cre)#Xya Pan-endothelial149 
Tie1 Tg(Tie1-cre)9Ref  
Pan-endothelial in embryonic and 
extraembryonic tissues, haematopoietic cells, 
subregions of the adult brain 150 
 
 
The Kdr gene encodes the VEGF receptor-2 which is expressed in the vascular 
endothelium and haematopoietic cells in the embryo upon E10 and in the adult heart, lung, 
kidney, brain and skeletal muscle 151. Generation of the transgenic mouse lines was either 
accomplished by fusing the 939 bp 5’ promoter and 2.3 kb 3’ enhancer of the Kdr gene 
with the cre gene 59 or by creating a knock-in mouse through replacing the first exon of the 
Kdr gene with the cre gene 142. Reporter activity was observed in arterial and venous ECs 
and sinusoidal endothelium of the FL at E11.5 59 but no data for adult liver Cre activity was 
demonstrated. So far, both transgenic mouse lines have not been utilised for LSEC specific 
investigation.  
The Tek gene encodes the Angiopoietin-1 receptor which is expressed in vascular ECs 
during embryogenesis and in the lung, heart, brain, liver and kidney of the adult mouse 152. 
Several strategies were developed to generate a transgenic mouse line. First of all, a 
sequence encoding cre under the control the Tek promoter was introduced into the 
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genome 57,144,148, second, the 2.1 kb promoter and 10 kb of the first intron of the Tek gene 
drive the cre expression 146,147, third, the 2.1 kb promoter and a 10.5 kb fragment of exon 1 
of the Tek  gene were ligated to the cre 153, and last, the promoter and first intron enhancer 
element of the Tek  gene  drive cre expression 145. Inclusion of the first intron enhancer 
into the targeting strategy was sufficient to drive recombination in adult vascular ECs 154. 
Cre activity in fetal LSEC was demonstrated by genetic inactivation of the IκB kinase β 155 
and in the adult liver endothelium by expression of the YFP reporter protein 156. The off-
target recombination in HSPCs was useful to study the function of the DNA excision repair 
protein ERCC-1 157 and the signal transducer and activator of transcription 5A/B 158 in 
haematopoietic cells.  
Off-target recombination in haematopoietic cells 128,157,158 or lymphatic cells 127 was 
circumvented by the generation of inducible endothelial specific transgenic mouse models. 
Fusing the tamoxifen-inducible cre either to the 2.5 kb promoter of the Cdh5 gene 159 or to 
the 200.3 kb promoter sequence of the Cdh5 gene on a bacterial artificial chromosome 
(BAC) clone 160 or to the open reading frame of the Cdh5 gene on a P1-derived artificial 
chromosome (PAC) construct 161 generated different Cdh5-creERT2 transgenic mouse lines. 
Cre activity was induced in venous and sinusoidal EC of the liver through several 
tamoxifen doses and caused a specific ablation of CXCR7 in LSECs 47. Other strategies to 
generate inducible endothelial-specific Cre driver lines include the fusion of the 
tamoxifen-inducible cre downstream of the 2.1 kb promoter and 10.5 kb first intron 
sequences of the Tek gene 162, the introduction of the tamoxifen-inducible cre into the first 
exon of the Tek gene obtained from a BAC clone 163 or the homologous recombination of 
the tamoxifen-inducible cre into the open-reading frame of the Pdgfb gene on a PAC 
construct 164. However, Cre activity of the resulting Tek-cre/ERT2 162,163 or Pdgfb-
icre/ERT2 164 has not been described in the hepatic microvasculature, yet.  
Endothelial-specific Cre driver mice are convenient to study the function of protein in ECs 
during embryogenesis and have proven Cre activity in ECs of almost all vascular beds. 
However, the off-target recombination in haematopoietic or lymphatic cells is 
disadvantageous if genetic inactivation is desired in LSECs.  Development of inducible 
endothelial Cre driver lines avoided the off-target recombination resulting from early 
embryonic Cre recombination that is transmitted to the descendant cells. Nevertheless, 
problem can occur due to the toxic effects of the tamoxifen 165, mosaic Cre activity 166 or 
inadequate recombination 167. Moreover, the development of a protocol for the tamoxifen 
treatment can be very time consuming. Consequently, if studying LSEC function in vivo Cre 
driver mouse lines are needed with an LSEC-restricted recombination.  
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4.1.2. LSEC-specific transgenic Cre driver lines 
LSEC-specific Cre driver lines were generated by insertion of the cre gene into the first 
exon of the Stab2 gene or of the Clec4g gene on a bacmid construct resulting in the Stab2-
cre or Clec4g-cre mouse line, respectively. Expression of Stab2 was observed in ECs lining 
the sinusoids in the liver, LN, BM, and spleen 27. Generation of the Stab2-cre transgenic 
mouse yielded two viable and fertile founder lines, the Stab2-cre f2 and Stab2-cre f3 mice. 
Clec4g is expressed by sinusoidal ECs of liver and LN among various species 100,168 and is 
also found in Kupffer cells 169. Generation of the Clec4g-cre transgenic mouse produced 
three viable and fertile founder lines, of which f12.5 demonstrated the most homogenous 
reporter expression in the hepatic endothelium during initial analysis and was chosen for 
further analysis.  
 
Table 2: Cre activity of the LSEC-specific transgenic Cre driver mouse lines by YFP or LacZ reporter 
expression 
Organ Cell type Stab2-cre f2 Stab2-cre f3 Clec4g-cre 
Liver 
microvascular EC | arterial 
and venous EC +   |   + +   |   + +   |   + 
other cell types - - - 
BM 
microvascular EC | arterial 
and venous EC +   |   + +   |   + - | - 
haematopoietic cells + - + 
LN 
microvascular EC | arterial 
and venous EC +   |   + +   |   + +   |   + 
haematopoietic cells + - + 
Spleen 
microvascular EC | arterial 
and venous EC +   |   + +   |   + -   |   - 
haematopoietic cells + - + 
Brain EC + - - 
Heart EC + - + 
Intestine EC + - - 
Kidney EC + - - 
Lung EC + - - 
Pancreas EC + + - 
Skin EC + - - 
Thymus EC + + - 
FL, E13.5 
microvascular EC | arterial 
and venous EC +   |   + -   |   - -   |   - 
haematopoietic cells + - + 
 
  
The Stab2-cre f2 mouse line targets LSECs in the adult and fetal liver. Cre activity was 
further observed in microvascular ECs of the LN, spleen and BM (summarized in Table 2). 
Moreover, Cre recombination was detected in ECs of all analysed organs and was 
identified in subsets of haematopoietic cells in the blood, BM, spleen, thymus, and the FL. 
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Cre activity in adult liver EC was utilised to investigate function of the protein wntless 
homolog (Wls) on metabolic zonation 170. Transcripts of Wls were 12.5-fold reduced in 
isolated liver ECs causing an altered liver to body weight ratio, loss of pericentral as well 
as expansion of periportal gene expression. Homogenous endothelial Cre activity in the 
Stab2-cre f2 mouse shows a clear benefit towards the inducible endothelial specific 
transgenic mouse models due to the mosaic genetic inactivation of Wls by Cdh5-cre/ERT2 
171. Next, BMP2 was abolished from the hepatic endothelium by using the Stab2-cre f2 
mouse 172. Levels of BMP2 mRNA were strongly decreased in the liver leading to a massive 
hepatic iron overload and in the peripheral blood. Finally, selective genetic inactivation of 
GATA4 in FL EC enabled the investigation of the LSEC differentiation in vivo 118 and 
avoided the embryonic lethality derived from cardiac defects when using the Tek-cre 
mouse 77. Here, the intersection of Stab2-cre f2 driven recombination and GATA4 
expression in LSECs allowed for the analysis of the effect of LSEC capillarization on liver 
organogenesis. Notably, Cre activity of the Stab2-cre f2 mouse in LSEC but not in cardiac 
EC during fetal development offers an advantage towards conditional endothelial Cre 
driver. Moreover, deletion of Wls and BMP2 in liver EC demonstrated homogenous Cre 
activity. However, off-target recombination in haematopoietic cells during embryogenesis 
and adulthood must kept in mind when using the Stab2-cre f2 mouse.  
The Stab2-cre f3 mouse line is a useful mouse model to target LSECs. Additionally, Cre 
activity was detected in microvascular EC of the LN, spleen and BM (summarized in Table 
2). Moreover, Cre recombination was detected in ECs of BM, liver, LN, spleen, pancreas, 
and thymus which make this mouse line a useful tool to investigate organ-specific 
endothelial functions. Compared to conditional endothelial-specific Cre mouse lines, the 
Stab2-cre f3 has the advantage that haematopoietic cells are not targeted in knockout 
studies. However, it has to be noted that the onset of Cre activity could not be determined 
in my experiments and that recombination is not as homogenous in the liver as for the 
Stab2-cre f2 mouse. In comparison to the Stab2-cre f2 mouse, the Cre activity of the Stab2-
cre f3 mouse resembles more closely the endogenous protein expression of Stab2. 
Differences in the Cre activity of founder lines were also observed for other transgenic Cre 
mice. The generation of the Prph-cre mouse produced four founder lines 173 and the 
differences between the transgene expression and endogenous protein expression derived 
either from the site of chromosomal insertion or local genomic effects on transgene 
expression  174. Higher copy number of the transgene could also cause differences between 
the founder lines or between transgene expression and endogenous protein expression. 
This was observed for the generation of the Myh11-cre 175 and the Prox1-cre 176 mice. 
Notably, the lowest numbers of transgene copies resulted in the most uniform reporter 
expression and higher copy number disturbed the transgene transcription most likely 
because of repeat-induced silencing of the transgene 176. Generation of transgenic mice 
with the help of BAC clones has the advantage that endogenous gene expression patterns 
are rather reflected due to the amount of genomic information that is transferred to the 
recipient genome 177 and the size of the BAC clone does not affect the transgenic efficiency. 
The more ectopic expression of the Stab2-cre f2 transgene compared with the Stab2-cre f3 
transgene is therefore either a result of different transgene copy numbers or the 
integration into a more open chromatin region.  
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The Clec4g-cre mouse line drives the Cre expression in LSECs. Cre activity was further 
identified in microvascular EC of the LN (summarized in Table 2) which makes this mouse 
line particularly advantageous in comparison to the Stab2-cre f2 mouse and Stab2-cre f3 
mouse in which Cre expression was also detected in sinusoidal EC of the spleen and the 
BM. In addition to that, Cre activity was observed in macrovascular EC of liver and LN as 
well as in the heart. This has to be kept in mind when studying proteins with a similar 
expression pattern like GATA4. Interestingly, Kupffer cells were not targeted by the 
Clec4g-cre mouse line but distinct subpopulations of myeloid cells in the BM, lung, 
pancreas, skin, and spleen displayed a reporter protein expression. Currently, there is no 
data available describing the CLEC4G protein expression in the mouse but gene expression 
data demonstrate transcript levels in liver, testis, spleen, and lung 104 which are in line 
with the observed reporter activity in those organs. Unfortunately, information regarding 
the cell type of expression is not available from this database 104. In human, CLEC4G is 
expressed by sinusoidal EC of liver and LN 100,101, in Kupffer cells 169 as well as in 
peripheral blood and in monocyte-derived macrophages and dendritic cells 178. Here, 
protein expression in human is only partly consistent with the transgene activity in the 
mouse which could be explained by different expression pattern across species. For 
example, porcine transcripts of CLEC4G were detected in the liver, LN and spleen 168 
although expression of CLEC4G in the spleen was neither described in human nor in 
mouse 104. 
 
4.1.3. Conclusion 
The Stab2-cre f2, Stab2-cre f3 and Clec4gCre mouse lines target the microvascular 
capillaries of the liver. All three transgenic mouse lines demonstrated Cre activity in the 
arterial and venous EC but neither were hepatocytes, Kupffer cells nor stellate cells 
targeted. Analogous to the expression pattern of the promoter gene, Cre activity was 
observed in sinusoidal EC of other organs. Reporter expression occurred in a varying 
degree in EC of other vascular beds which is either a result of the transgene integration 
into the genome or a result of a recombination event early during development causing all 
progeny cells to express the reporter.  
Transgenic mouse models have been developed to target selectively organ-specific ECs in 
organs apart from the liver. In contrast to the sinusoidal endothelium of the liver, the brain 
microvasculature constitutes a physical barrier that strictly regulates the entry of 
nutrients and substances into the brain. Due to its relevance for pharmacotherapy 179 or 
during neurological disorders 180 and because of the difficulties to model the blood-brain 
barrier in vitro 181 many researches aimed to target specifically brain ECs by the Cre/loxP 
system. Two promising mouse models were developed in the past that achieve a degree of 
brain endothelial specificity. The Tg(Sftpa1-cre)1Xya mouse line in which Cre expression 
is controlled by the surfactant protein A demonstrated Cre activity in blood vessels of 
brain, in distinct alveolar cells and epithelial cells of stomach 182. Selective genetic 
inactivation of the mothers against decapentaplegic homolog 4 protein in brain ECs 183 and 
lineage tracing of cerebrovascular ECs 184 established this mouse lines as a useful tool for 
targeting the blood-brain barrier. Additionally the off-target recombination in the gastric 
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epithelium allowed for the investigation of the PTEN/Akt signalling during gastric 
tumorigenesis 185. Second, the Tg(Slco1c1-icre/ERT2)1Mrks mouse line in which Cre 
activity is under the solute carrier organic anion transporter 1c1 promoter and is induced 
by tamoxifen 186. Recombination in brain ECs allowed the investigation of fever responses 
186–188 or amyloid β clearance during Alzheimer’s disease 189.  
 
4.1.4. Perspectives 
Although the Cre/loxP system provides a powerful tool to study function of proteins or to 
track cell fate decision in vivo, a disadvantage of this technique is that it cannot be applied 
for the use in humans. Therefore, genetic tools were developed that can be translated into 
the clinics. Modification of gene expression in LSECs can be beneficial during endothelial 
dysfunction in hepatic cirrhosis 190,191 or in order to target the tumour endothelium during 
HCC progression 192,193 
Viral vectors were engineered to modify gene expression in the target cells. The efficient 
transduction of genes into the genomes without transferring viral proteins have proven 
them useful and safe 194. Retroviral and lentiviral vectors as well as the recombinant 
adeno-associated virus, recombinant simian virus 40 and recombinant adenovirus are 
commonly used as viral tools 194. The high endocytic capacity of LSECs is suitable but in 
order to avoid viral tropism, surface receptors on the target cells were used to direct viral 
transduction. The specific transduction of LSEC in mouse and human by a modified 
lentivirus has been investigated by Abel et al. 195. Endoglin on LSECs was targeted by 
single-chain variable fragment fused to the measles virus haemagglutinin envelope 
protein. Systemic administration of the mouse Endoglin-specific lentiviral vector 
transduced 98% of all liver ECs, only a small fraction was found in F4/80+ Kupffer cells. 
The human counterpart of the Endoglin-specific lentiviral vector was shown to specifically 
infect human LSECs while leaving murine LSECs unaffected.  
Beyond viral approaches, other methods have been employed to manipulate gene 
expression in LSECs, which include transfection of DNA, RNA interference via small 
interfering RNA (siRNA) or clustered regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated protein 9 (Cas9) system. Nonviral transfer of nucleic acids 
into LSECs is either facilitated by lipid-based  drug  carrier systems 196 or by hydrodynamic 
injections 197. With the help of hydrodynamic injections, “naked” DNA is injected into the 
tail vein and arrives in the liver via the CV which often led to a disruption of the sinusoids 
and enlargement of the fenestrae in the pericentral region 198. This makes this method 
more applicable for drug delivery into hepatocytes than into LSECs. On the other hand, 
LSEC are not quite susceptible for the interaction or uptake of liposomes 196. Therefore, 
modifications of the liposomal surface with substrates that are taken up by scavenger 
receptors are advantageous. Kamps et al. increased the liver uptake 17-fold by coupling 
the poly-aconitylated human serum albumin to liposomes without affected the spleen 199. 
The liposomes are mainly taken up by LSECs and Kupffer cells dependent on the liposomal 
size. Marquez et al. developed chondroitin sulphate functionalized nanoparticles 200. 
Incorporation of plasmid encoding for EGFP into the nanoparticles demonstrated a 
delivery into LSECs via Stab2 mediated endocytosis but not into Kupffer cells.  
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Recent advances in the field of genetic modification and editing were achieved through the 
discovery and engineering of the CRISPR/Cas9 system. In brief, this technique consists of 
the single guide RNA that directs the Cas9 encoded RNA-guided nuclease to a target 
sequence in order to induce a double strand break 201. During the following DNA repair the 
homologous recombination in conjunction with an exogenous template DNA can insert 
foreign genetic material into the host genome or the nonhomologous end joining induces a 
frameshift mutation leading to a gene knockout. The usefulness for liver specific gene 
modification was demonstrated by few studies 202–205. Although, the focus of these 
researches was on hepatocytes, these strategies could also be applied towards LSECs.  
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4.2. Differentiation of liver sinusoidal endothelial cells 
The TF GATA4 was identified by our group in a set of TFs to be required for the LSEC 
specific differentiation programme in vitro 24. As LSECs are difficult to manipulate in vitro 
and because in vivo studies of GATA4 demonstrated an indispensable role during heart 
development 75–78,86,206,207, investigation of GATA4 function in LSECs required a cell-type 
specific inactivation. We therefore screened Cre expressing transgenic mouse lines for 
suitability to induce an LSEC restricted knockout and mated this mouse with mice 
homozygous for the Gata4loxP allele to generate a conditional knockout mouse. 
Expression of GATA4 in fetal LSECs was confirmed and the Stab2-cre f2 mouse line 
was applied to generate the LSEC restricted GATA4 inactivation (Gata4∆LSEC) that resulted 
in an embryonic lethality and liver-restricted growth arrest as well as an endothelial 
dysplasia. Expression of GATA4 was lost in 90% of the FL ECs in Gata4∆LSEC knockout 
embryos. Upon GATA4 deficiency, the FL sinusoids underwent a phenotypical shift that 
was characterised by an adoption of continuous endothelial marker profile, formation a 
basement membrane and increase of perisinusoidal ECM.  As a result, the capillarized FL 
endothelium prevented the seeding of embryonic haematopoietic progenitor and stem 
cells into the FL and caused a lethal anaemia. 
 
4.2.1. Liver sinusoidal endothelial-derived GATA4 is vital for fetal liver 
growth 
The conditional inactivation of GATA4 by the Stab2-cre f2 mouse resulted in a reduced FL 
size and embryonic lethality. Although GATA4 transcripts were observed in the adult liver 
73,208, here, expression of GATA4 was demonstrated in fetal LSECs as early as E10.5. In 
order to study function of GATA4 on LSEC differentiation a proper selection of a suitable 
Cre driver line was important due to reported lethal phenotypes 75–77. The Stab2-cre f2 
mouse displayed the required reporter activity in LSECs but also in FL haematopoietic 
cells as well as in ECs of AGM region, brain, midgut, somites. Off-target effects due to an 
overlap of the Cre activity and GATA4 expression were excluded because, first, the 
described role of GATA4 in FL haematopoietic cells did not represent endogenous protein 
expression 209–211, second, function of GATA4 in somites or AGM region has not been 
described, yet, and, third, expression of GATA4 in the brain 212 or intestine 213 was only 
reported for non-endothelial compartments. Consequently, the only overlap of GATA4 
expression and Cre activity of the Stab2-cre mouse occurs in the FL sinusoidal 
endothelium. 
Loss of GATA4 in fetal LSEC upon E10.5 affects the expansion of the FL immediately. The 
liver primordium is formed around E9.5 and expands rapidly in the subsequent period 60. 
GATA4 was reported to play a role for the growth of the FL either as a transcriptional 
regulator in mesenchymal cells originating from the STM before E9.0 62, by compensating 
the loss of GATA6 214 or through the interaction with FOG-2 78. Cre activity of the Stab2-cre 
f2 mouse in mesenchymal cells has not been observed and the compensatory function of 
GATA4 and GATA6 is lost after E9.5 214. FOG-2 is a transcriptional regulator of GATA4 215 
and genetic inactivation of FOG-2 caused an embryonic lethality due to multiple cardiac 
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abnormalities with secondary defects in lung and liver development 216. Expression of 
FOG-2 in livers of Gata4∆LSEC embryos has not been investigated and an endothelial 
function of FOG-2 has not been published, yet. Therefore, a possible role of FOG-2 on the 
liver hypoplasia of the Gata4∆LSEC embryos cannot be excluded.  
 
4.2.2. GATA4 is required for sinusoidal differentiation of the fetal liver 
microvasculature 
Reduction of GATA4+ nuclei in Stab2-expressing fetal LSECs of Gata4∆LSEC embryos were 
clearly seen as early as E10.5. Before E10.5, the FL is characterised by a simple sinusoidal 
vascular network with high expression of CD31 that is progressively lost during 
development and by low expression of sinusoidal marker that gradually increase during 
hepatic maturation 28–30. Loss of GATA4 expression during this period prevents the 
differentiation from the primitive FL vasculature towards sinusoidal microvascular ECs. 
Factors that drive sinusoidal differentiation and specification were described for the adult 
liver. Rspo-3 is an angiocrine factors which is secreted by EC from the CV and was 
essential for establishment and maintenance of liver zonation 70. Hepatocyte growth factor 
(HGF) is secreted by LSECs and stimulated liver regeneration in a model of partial 
hepatectomy 217. LSEC-derived Wnt-2 promoted LSEC proliferation and induced VEGF 
receptor-2 signalling in cultivated LSECs 51. Moreover, Wnt-2 was identified in a 
comparative gene expression profiling to be specific for the LSEC differentiation 
programme in vitro 24. Similar to Wnt-2, BMP2 was specifically expressed in LSECs 
compared to LMECs and was lost during dedifferentiation ex vivo 24. Conditional genetic 
inactivation of the angiokines by Stab2-cre f2 did not results in dedifferentiation of the FL 
sinusoids or defects in liver development 118 indicating that LSEC-derived Rspo-3, HGF, 
Wnt-2, and BMP2 do not participate significantly in liver development.  
Similar to GATA4, hypoxia-inducible transcription factor 1 subunit β (Hif-1β) was 
essential for liver organogenesis 218. Loss of function in ECs caused partial an embryonic 
lethality during late-gestation with a distorted hepatic vascular architecture, severe 
hypoglycaemia and downregulation of genes involved in gluconeogenesis. Less than 10% 
of knockout mice survived until adulthood and suffered from weight loss as well as they 
developed a hepatic portal arteriolar hyperplasia and a portal fibrosis with collagen and 
iron deposition. In contrast to GATA4 that regulated sinusoidal differentiation during early 
stage of liver development leading to an embryonic lethality at mid-gestation, endothelial-
derived Hif-1β was essential for maintenance of the mature liver microvasculature with 
secondary defects in glucose metabolism. Additional factors known to be involved 
sinusoidal specification are TF Rbpj which mediates all canonical Notch signalling 219. 
Notch signalling from hepatic EC regulated sinusoidal diameter and controlled vascular 
shunting in the newborn and adult mice. Disruption of Rbpj transcriptional activity caused 
liver endothelial malformations most likely through VEGF receptor-3 dysfunction and is 
further aggravated by an aberrant ephrin-B2 signalling. Liver X receptor α was shown to 
be involved in LSECs capillarization in a model of CCl4-induced fibrosis 220. LSEC 
capillarization was regulated through Hedgehog signalling in vitro and in vivo and was 
further diminished by liver X receptor α agonist treatment. Although these signalling 
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pathways were critical during specification and maintenance of the mature hepatic 
microvasculature, GATA4 possess superordinate functions during liver sinusoidal 
development which were elaborated here. 
 
4.2.3. Loss of liver endothelial-GATA4 induces a hepatic fibrosis in the 
embryo 
The capillarization of the FL endothelium contributes to the increase of ECM. Similar to the 
FL of Gata4∆LSEC embryos, Delgado et al. observed a FL fibrosis by inactivating GATA4 in 
STM derived cells 80. The utilised G2-Cre mouse recombined in hepatic mesothelial, stellate 
and ECs 80 in contrast to the Stab2-cre f2 mouse which inactivated GATA4 in FL EC. 
Comparison of both mice, Gata4∆LSEC and G2-Cre;GATA4, indicates that the increase of ECM 
derives either from the GATA4-deificent endothelium or from an impaired hepatic 
vascular niche. In ECs GATA4 could repress the synthesis of pro-collagens or activate the 
transcription of matrix metalloproteinases which would lead to an increase of collagen or 
a decrease of matrix metalloproteinases activity in the Gata4∆LSEC embryo, respectively. 
Indeed, binding sites of GATA4 were found in regulatory elements of the human COL1A2 
gene. Binding of GATA4 to the promoter sequence was demonstrated to inhibit the 
expression of collagen α-2(I) chain 221,222. Another possible explanation is that the 
capillarized endothelium attracts myofibroblasts similar to the adult liver fibrosis 223. In 
response to VEGF, LSEC derived nitric oxide contributed to the activation of stellate cells 
54, however, no expression of endothelial nitric oxide synthase was observed in the FL 
224,225. But it was shown that LX2 stellate cells preferred adhesion on Laminin α-4 which 
was increased in the FL of Gata4∆LSEC embryos 118. The contribution of other LSEC-derived 
angiokines should be taken into consideration. Endothelial derived Kruppel-like factor 2 
had an impact on liver regeneration 226 and contributed to stellate cell deactivation 227 and 
the transforming growth factor β acted in a pro-fibrotic manner and led to the 
transdifferentiation of hepatic stellate cells into myofibroblasts 228. 
 
4.2.4. Proper sinusoidal differentiation is required for fetal liver 
haematopoiesis 
HSPCs in FLs of Gata4∆LSEC embryos were functionally potent but demonstrated an inability 
to generate sufficient amounts of progeny in the FL. During fetal haematopoiesis HPCs are 
generated in the AGM region and migrate around E11 into the FL in order to proliferate 
and differentiate 66. HPCs accumulation in the fetal blood and the increase of VE-Cadherin 
in the FL endothelium indicates that the capillarization in livers of Gata4∆LSEC embryos 
prevented seeding of HSPCs into the FL. It was demonstrated by Dartsch et al. that an 
increased tightness of the FL endothelium impaired the immigration of HPCs into the FL as 
well  69. The covalent linking of VE-Cadherin to α-Catenin caused a liver hypoplasia and an 
increase of HPCs in the blood despite their potential to differentiate into the myeloid 
lineage. This indicates that a proper endothelial phenotype is needed for seeding of HPCs 
into the FL. Rantakari et al. observed an impaired exit of differentiated monocytes into the 
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fetal blood due to the lack of diaphragms in fetal LSECs 229. Here, the authors argued that 
the PLVAP+ diaphragm in fetal LSECs provided a surface to interact with chemokines or 
monocytes. These studies show that the discontinuity and proper fenestrations of LSECs 
are crucial for seeding and exit of haematopoiesis cells. Additionally, Kajikhina et al. 
provided evidence that cytokines from FL EC contributed to the homing and lineage 
differentiation of progenitor cells 230. The authors showed that LYVE1high ECs and 
CD166high mesenchymal cells produced cytokines for the transendothelial migration of 
progenitor cells into the liver emphasizing by that the role of the vascular niche on FL 
haematopoiesis. 
 
4.2.5. Conclusion  
The results presented here provide insight into the function of GATA4 in LSECs. Sinusoidal 
differentiation from the primitive hepatic capillaries was dependent on the transcriptional 
activity of GATA4. Loss of sinusoidal differentiation impaired seeding of HPSCs and 
prevented growth of the FL. The contribution of GATA4 co-factors, such as FOG-2, on 
sinusoidal differentiation remains elusive. There are still open questions on how GATA4 
regulates sinusoidal differentiation maybe through activation of signalling pathway like 
the Erbb3-Erk pathway in cardiac-derived ECs 77 or by regulating the transcription of 
angiocrine factors. 
Similar to GATA4, other TFs are known to drive cell fate decision of ECs during fetal 
development. The TF PROX-1 is a well-studied master regulator for specifying the 
lymphatic EC fate. Mice that were deficient for PROX-1 die during embryogenesis with 
severe defects of lymphangiogenesis and an inability to generate lymphatic ECs 231,232. 
Overexpression of PROX-1 in blood vascular ECs induced typical marker for the adult 
lymphatic vasculature and, vice versa, repressed marker for vascular ECs 233,234. The Notch 
pathway regulates the arterial cell fate decision through signalling between adjacent cells 
235. In the zebrafish, notch1 expression regulates the zebrafish orthologue Hey2 which 
induces the arterial marker ephrin-B2 and represses the venous marker EphB4 receptor 
236,237 and in mice Notch ligand delta like ligand-4 controlled the arterial specification in a 
dosage dependent manner 238. Conversely, the TF COUP-TF 2 was shown to regulate the 
venous identity by upregulating arterial marker and downregulating of venous marker 239.  
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4.2.6. Perspectives 
Similar to GATA4, LIM-domain-only (Lmo) protein 3, TF EC (Tfec) and c-Maf were 
identified to be induced upon LSEC dedifferentiation and to be preferentially expressed in 
LSECs when comparing to lung microvascular ECs 24.  
Lmo proteins act as scaffolding proteins in order to regulate transcription and Lmo3 was 
primarily associated with oncogenic functions during neurological disorders 240. In LSECs, 
Lmo3 counter-regulated the GATA4-mediated activation of autocrine BMP2 signalling 
presumably via the BMPR1-SMAD1 axis and without affecting the GATA4 induced 
transcriptional programme 241. Since Lmo3 knockout mice survived until adulthood and 
displayed no phenotypical abnormalities in the brain 242, functional implication on LSECs 
during challenging conditions like liver metastasis remains to be investigated.  
Tfec acts as a transcriptional inhibitor and is transcribed at low levels during fetal 
development and in the adult liver as well as at high levels in the spleen, lung and kidney 
243. Although Tfec mutant mice did not show any gross abnormalities 244, the related TF 
Tfeb is involved in the extraembryonic vascularization by regulating VEGF expression in 
the placenta 245. In the zebrafish, tfec is expressed in ECs of the CHT and regulated the 
secretion of cytokines from ECs and promoted directly HSC expansion in the CHT 246.  
C-Maf belongs to a family of proto-oncogenes and demonstrated versatile functions by 
being involved in the development of the skin 247, of the cartilage 248 and eye 249,250. The 
genetic inactivation of c-maf produced different phenotypes as either a viable knockout 
mouse was generated with a reduced cell size in the kidney and liver 251 or an embryonic 
lethality was observed with a liver hypoplasia and defects in FL erythropoiesis 252. Here, 
the different genetic backgrounds of the mice resulted in different phenotypes since either 
Balb/c mice 251 or C57BL/6J mice on a 129/Sv background 252 were used for the 
experiments. Although the defective FL erythropoiesis of the c-maf knockout embryos 
emerged from a defect of the adhesive function of the macrophages 252 it would be quite 
intriguing to investigate c-maf function in LSECs.  
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5. Material and methods 
5.1. Methods 
5.1.1. Animal experiments 
5.1.1.1. Generation of Stab2-cre and Clec4g-cre transgenic mouse lines 
A BAC encoding the genomic Stab2 (RPCIB731O23129Q) or Clec4g locus 
(RPCIB731A07239Q) was obtained from SourceBioscience. A cDNA containing a codon 
improved version of cre recombinase 253 followed by polyA signal sequence was fused into 
exon 1 of Stab2 (Figure 28) or Clec4g via homologous recombination 254. In frame 
recombination into Stab2 or Clec4g was realized via PCR added homologous arms of 45 bp 
in length flanking the 5’ and 3’ region of the start codon. Correct Stab2-cre or Clec4g-cre 
recombinant BAC were confirmed by sequencing and linearized, purified with Sepharose 
CL4B (GE Life Science), and injected into the pronuclei of fertilized C57Bl/6NCRL oocytes. 
Three B6.Stab2tg1.1-3cre transgenic founder mice (f1, 2 and 3) or B6.Clec4Gtg1.1-3cre transgenic 
founder mice (f12.5, 18.3 and 20.1) were identified by PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28 : Generation of the Stab2-cre transgenic construct.
The cDNA of the Cre recombinase was amplified by PCR and inserted into the exon 1 of Stab2 on a bacmid 
by homologous recombination. Positive clones were selected by ampicillin resistance; flip mediated 
recombination of the ampicillin cassette generated the final Stab2-cre transgenic construct.  
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5.1.1.2. Animal housing and breeding 
Animals were housed in a temperature- and humidity-controlled room with a 12 h/12 h 
light/dark cycle (lights on 6 am - 6 pm) and had access to food and water ad libitum. All 
animal experiments were approved by the Medical Ethics Committee II of the Medical 
Faculty Mannheim of the University of Heidelberg and filed with local authorities 
(Regierungspräsidium Karlsruhe). This research was performed on a mixed C57BL/6 and 
129/Sv background. 
Cre driver strains (Stab2-cre, Clec4g-cre) were characterized by R26LacZ 
[Gt(ROSA)26Sortm1Sor] reporter mouse 92 or R26YFP [Gt(ROSA)26Sortm1(EYFP)Cos] reporter 
mouse 93. Homozygous floxed reporter mouse was bred with cre driver mouse resulting in 
the following cre;reporter mouse strains: f2;LacZ, f3;LacZ, f2;YFP, f3;YFP, and f12.5;YFP. 
The offspring of the F1 generation was analysed during embryogenesis or at the age of two 
month to one year. 
Conditional deletion of GATA4 was achieved by breeding homozygous floxed Gata4 mouse 
(Gata4tm1.1Sad) 79 with cre driver mouse resulting in a heterozygous GATA4 knockout F1 
generation. Mice from the F1 generation were bred with homozygous floxed Gata4 mouse 
resulting in the Gata4∆LSEC knockout.  
Triple mutant mice resulted from breeding homozygous floxed Gata4;YFP mouse with 
heterozygous GATA4 knockout F1 generation. The F2 generation was Stab2-cre driven 
GATA4 deficient and displayed reporter YFP expression (Gata4∆LSEC;YFP).  
 
5.1.1.3. Dissection of adult organs, embryos and fetal organs 
Mice were killed by cervical dislocation and the organs of interests were dissected.  
Aged-matched embryos were generated by timed mating. Females of at least 12 weeks 
were mated with males of at least 10 weeks. Two to three females were placed into the 
cage of the male over night, the noon of the day of the vaginal plug was considered as E0.5. 
Pregnant mice were sacrificed by cervical dislocation, tissues belonging to the mother, 
such as womb and fat, were removed. Then the placenta was removed, the yolk sac was 
cut gently and separated from embryo proper by tearing off the umbilical and vitelline 
vessels. Dissection was carried out under a transmitted light base microscope and YS were 
collected for genotyping. 
For dissection of fetal heart and liver, embryos were placed in ice cold phosphate buffered 
saline (PBS) under a transmitted light base microscope and head was cut away. The chest 
and rip cage were opened and heart was dissected. The liver was identified as the largest 
peritoneal organ with its characteristic colour and shape. It was dissected by opening the 
fetal body laterally, removing the liver and eliminating gastrointestinal anlagen.  
 
5.1.1.4. Transplantation  
Experiments were performed in cooperation with the AG Rodewaldt from German Cancer 
Research Centre (Heidelberg).  
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FLs were mechanically dissociated and passed through a 100 μm cell strainer (BD). After 
incubation with purified mouse IgG (500 μg/ml, Jackson ImmunoResearch Laboratories) 
in 5% FCS/PBS the cells were stained with commercial antibodies in 5% FCS/PBS on ice 
for 30 min. LSK cells were isolated by electronic deposition into individual wells of a U-
bottom 96-well plate containing 100 µl sterile 50% FCS using a FACS AriaIII (BD). The 
number of sorted cells ranged between 150 and 850 cells. Prior to injection, 100 μl sterile 
PBS was added to each well, and cells were injected intravenously into individual Rag2-/-
;γc-/-;KitW/Wv recipients 117. Peripheral blood samples were collected 4, 10 and 15 weeks 
after transplantation from the submandibular vein into EDTA-containing microtubes 
(Sarstedt) to screen for progeny of donor cells (detected by the congenic marker CD45.1). 
Red blood cell lysis was performed by using RBC Lysis Buffer (BioLegend) to enrich for 
white blood cells. For FACS staining, the following antibodies were used: CD3e eFluor780 
(clone 17A2, # 47-0032-80, eBioscience), CD11b PE-Cy7 (clone M1/70, # 25-0112, 
eBioscience), CD45.2 PE (clone 104, #12-0454, eBioscience), CD45.1-FITC (clone A20-1.7, 
#561871, BD), Gr-1 APC (RB6-8C5, # 553129, BD), CD19 QDot605 (clone 6D9, #Q10379, 
Invitrogen).  
 
5.1.2. Histological techniques 
5.1.2.1. Paraformaldehyde perfusion and pre-treatment 
In order to analyse the fluorescent reporter protein of the cre;reporter mouse strains or 
triple mutant mice, adult animals were perfused or embryos were pre-fixed. For the 
adults, mice were anesthetized by intra-peritoneal injection of Ketamine/Xylazine 
anaesthesia with a dosage of 0.1 ml per 10 g of body weight. As soon as the mice were 
unresponsive, the abdomen was opened until the diaphragm was exposed. The diaphragm 
was cut through and the thoracic cavity was opened by cutting the ribs away. A 25 G 
butterfly needle was inserted into the left cardiac chamber and the animal was flushed 
with PBS at 1 ml per min. When blood has been cleared from body (after 10 -15 min), the 
perfusion switched from PBS to 4% paraformaldehyde (PFA) and the mice were perfused 
at 2 ml per min for 20 – 25 min. The perfusion was stopped; the organs of interest were 
excised and immersion-fixed over night at 4 °C.  For the foetus, age-matched embryos 
were harvested as described, rinsed in PBS and fixed in 4% PFA over night at 4 °C.  
 
5.1.2.2. Decalcification of tibia and femur 
Bones were collected after perfusion and fixed in 4% PFA over night as described. The 
following day, bones were washed with PBS and decalcified in 10% EDTA / PBS at 4 °C on 
a tube roller up to two weeks while changing EDTA solution every three days. 
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5.1.2.3. Cryo-protection, -embedding and -sectioning 
Pre-fixed organs and embryos were washed three times in PBS and cryoprotected in 30% 
sucrose over night at 4 °C. Next day, organs were placed in cryomolds, embedded within 
optimal cutting temperature (OCT) compound, slowly frozen in the gas phase of liquid 
nitrogen until the OCT becomes solid and finally frozen in liquid nitrogen for several 
minutes. Non-prefixed organs and embryos were embedded in OCT equally. Tissue was 
stored at -80 °C, transferred to the cryotome on dry ice and sections of 8 µm were melted 
on adhesion microscope slides.  
 
5.1.2.4. Paraffin embedding and -sectioning 
PFA fixed tissue was put into embedding cassettes dehydrated through a series of 
increasing concentration of ethanol and cleared in xylene. Paraffin wax infiltrated the 
tissue at 60 °C and the tissue was embedded into paraffin blocks. 1- 5 µm sections were 
cut at a microtome, flattened out in a water bath and melted on adhesion microscope 
slides. 
 
5.1.3. Staining procedures 
5.1.3.1. Beta-galactosidase assay 
The f2;LacZ and f3;LacZ embryos ranging from E9.5 to E10.5 were assessed for whole 
mount β-galactosidase staining. For this purpose, freshly dissected f2;LacZ and f3;LacZ 
embryos were rinsed in ice cold PBS and incubated in β-galactosidase staining solution at 
37 °C over night on a falcon tube roller to ensure even distribution of the staining solution. 
Next day, embryos were washed with PBS and photographed with a transmitted light base 
microscope.  
 
5.1.3.2. Immunofluorescent staining procedures 
Cryosections from non-prefixed organs were dried one hour, fixed in acetone or in 4% PFA 
(for nuclei staining) for 10 min at RT, rinsed in PBS and permeabilized in 0.1% PBS + 
Triton X-100 for 3 min in case of nuclei staining. Autofluorescence was quenched with 50 
mM NH4Cl for 15 min and epitopes were blocked with 10% FCS/ PBS for 60min. The 
incubation with a biotinylated primary antibody required an avidin/biotin block. For this 
purpose, sections were incubated with avidin solution for 15 min after regular blocking, 
rinsed with PBS and incubated then with biotin solution for another 15 min. Sections were 
then treated with first antibody over night at 4 °C, washed three times with PBS and 
secondary antibody was applied. Primary and secondary antibodies were diluted in 0.01% 
FCS/PBS and incubated in a humidity chamber. Finally, sections were washed three times 
with PBS, once with dH2O and mounted with fluorescent mounting medium. 
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Cryosections from PFA prefixed tissue were treated as follows. Epitopes were blocked in 
immunofluorescent block buffer for 60 min and first antibody was incubated over night at 
4 °C. After three washing steps, secondary antibody was applied for 45 min. Primary and 
secondary antibodies were diluted in 20% immunofluorescent block buffer/ PBS and 
incubated in a humidity chamber. Sections were washed three times with PBS, once with 
dH2O and mounted in fluorescence mounting medium. Fluorescent specimens were 
imaged with a multi-photon laser scanning microscope or confocal laser scanning 
microscope.  
 
5.1.3.3. Immunohistochemical staining procedures 
Cryosections were dried one hour, fixed in acetone for 10 min at RT and rinsed in PBS. 
Endogenous peroxidase activity was blocked with peroxidase block for 10 min and 
epitopes were blocked with 10% FCS/ PBS for 60 min. After incubation with first antibody 
over night at 4 °C, sections were washed three times with PBS and secondary antibody 
was applied Primary and secondary antibodies were diluted in 0.01% FCS and incubated 
in a humidity chamber. Sections were then incubated in AEC substrate until desired signal 
intensity was produced (5 to 20 min depending on the tissue and antibody) and 
counterstained with Mayer’s Haematoxylin. Finally, sections were washed three times 
with PBS, once with dH2O and mounted with aqueous mounting medium. Images were 
captured with an upright microscope Eclipse Ci-E or an upright motorized microscope 
Eclipse Ni-E.  
 
5.1.3.4. Histological staining 
H&E and Sirius Red staining was carried out on paraffin sections according to routine 
protocols in the local pathology department.  
 
5.1.3.5. Electron microscopy 
Experiments were carried out in cooperation with the electron microscopy core facility (K. 
Richter) from German Cancer Research Centre (Heidelberg). FLs from embryos were 
dissected and immediately immersed in fresh fixative for epoxy-embedding for several 
hours. Post-fixation in buffered 1% osmium tetroxide, dehydration, and resin-embedding 
were carried out according to standard protocols at the core facility. Ultrathin sections (60 
nm) were contrast-stained with lead citrate and uranyl acetate and observed in an 
electron microscope at 100 kV. Micrographs were taken with image-plates, scanned at 30 
µm resolution (Ditabis).  
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5.1.4. Cell isolation procedures 
5.1.4.1. Isolation of peripheral blood mononuclear cells   
Mice were anesthetized with 5% isoflurane and 400 ml/min oxygen flow rate. Blood was 
sampled from the retrobulbar venous plexus with a 20 µl micropipette into Lithium 
Heparin microvettes. Blood was diluted in an equal volume with PBS and was added 
slowly on top of 2 ml of Biocoll solution and centrifuged for 20 min at 300 x g at room 
temperature (RT). The intermediate cloudy phase was transferred into a new tube and 
washed once with PBS.  
 
5.1.4.2. Isolation of cells from spleen, thymus, and bone marrow 
For isolation of splenic and thymic cells, organs were minced in PBS, filtered through a 70 
µm cell strainer and washed once in PBS.  
For isolation of BM cells, tibia and femur were flushed with PBS via a 26 G needle and cell 
suspension was passed through a 70 µm cell strainer.  
 
5.1.4.3. FACS 
FACS experiments were either performed according to our protocol or in cooperation with 
the AG Rodewaldt from German Cancer Research Centre (Heidelberg).  
 
5.1.4.3.1. Analysis of the reporter mice 
Results in Figure 8 G, H, Figure 11 B, E, H, Figure 12 I were obtained from experiments 
carried out in cooperation with the group of Prof. H. R. Rodewaldt, DKFZ, Heidelberg. The 
FLs of embryos were harvested (see section 5.1.1.3) and resuspended in 1 ml 10% FCS in 
Hanks' Balanced Salt Solution (HBSS), centrifuged at 500 x g for 1 min and the pellet 
incubated in 1 ml Calcium deprived medium supplemented with 25 µl collagenase IV 
(Sigma C2675, 50 mg/ml) and 15 µl DNAse I (Fermentas #EN0521, 1 U/µl) at 37 °C for 30 
min. Single cell suspensions were then incubated with directly labelled antibodies (CD146 
PE 1:100, CD45 PE Cy7 1:400, CD117 APC 1:400, Sca1 PCPCy5-5 1:200) for 30 min at 4 °C. 
Single cell suspensions of BM, spleen, thymus and blood from adult f2;YFP and f3;YFP 
were prepared as described in section 5.1.4.1 and 5.1.4.2. Cells were washed in 10% 
FCS/HBSS, blocked in purified mouse IgG (500 µg/ml in 10% FCS/HBSS) for 20 min on ice 
and washed in 10% FCS/HBSS. Single cell suspensions from spleen were incubated with 
directly labelled antibodies (CD3 APC-Cy7, CD19 Qdot, CD11b PE-Cy7, and Gr1 APC) for 30 
min at 4 °C. Cells from thymus were incubated with directly labelled antibodies (CD3 APC-
Cy7, CD4 PE Cy7, and CD8 APC) for 30 min at 4 °C. Cells from BM and blood were first 
incubated with primary antibodies (CD3, CD4, CD8, CD11b, CD19, Gr1, Ter119; all 
biotinylated) for 30 min at 4 °C. Cells were then washed with 10% FCS/HBSS and 
incubated with streptavidin APC-Cy7 secondary antibody for lineage negative gating and 
with directly labelled antibodies (CD117 A700 1:400, CD48 PE 1:200, Sca1 PerCP-Cy5.5 
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1:200, CD150 BV605 1:100, CD16/32 PE-Cy7 1:400, CD34 APC 1:25) for 30 min at 4 °C. 
Cells were washed once with 10% FCS/HBSS, resuspended in 100 µl 10% FCS/HBSS 
supplemented with 100 µl Sytox and analysed on a FACS Fortessa (BD) and data were 
evaluated using FACS Diva software (BD).  
Results in Figure 11 A, C, D, F, G, I and Figure 17 were obtained from experiments carried 
out in our facility. Single cell suspensions were prepared as described in section 5.1.4.1 
and 5.1.4.2 and incubated in 100 µl (pBMCs, BM) or 200 µl (spleen) of 10% Fc block/FACS 
buffer for 20 min on ice. After that, the cell concentration was adjusted with FACS buffer to 
one million cells per ml and incubated in 100 µl FACS buffer containing 1 µl of the 
respective antibody for 20 min on ice protected from light. Cells were washed once in 
FACS buffer, analysed with FACS-Canto™ II and data were evaluated using FlowJo V 10.1 
software. 
 
5.1.4.3.2. Analysis of GATA4 knockout embryos 
Results in Figure 26 and Figure 27 were obtained from experiments carried out in 
cooperation with the group of Prof. H. R. Rodewaldt, DKFZ (Heidelberg). YS were 
harvested and digested in HBSS/10% FCS containing collagenase IV (60 U/ml f.c., Sigma) 
and DNase I (25 µg/ml f.c., Sigma) for 1 h at 37 °C. FLs were harvested, mechanically 
dissociated and passed through a 100 µm cell strainer (BD). Embryo remnants were 
exsanguinated into defined volumes of HBSS/10% FCS and blood samples were washed 
twice with PBS/5% FCS. Single cell suspensions were washed with PBS/5% FCS and Fc 
receptors were blocked by incubating cells with purified mouse IgG (500 mg/ml, Jackson 
ImmunoResearch Laboratories). All stainings were performed in PBS with 5% FCS on ice 
for 30 min with optimal dilutions of commercially-prepared antibodies. Reagents used 
were CD3e phycoerythrin (PE) (clone 145-C11, #12-0031-80), CD11b PerCP-Cy5.5 (clone 
M1/70, #45-0112-80), CD16/32 PE-Cy7 (clone 93, #25-0161-81), CD34 eFluor660 
(RAM34, #50-0341-80), CD45 PE-Cy7 (clone 30-F11), CD45APC-eFlour780 (clone 30-F11, 
#47-0451-80), CD48 APC (clone HM 48-1, # 17-0481-80), CD117 A700 (ACK-2, #56-1172-
80), F4/80 APC (clone BM8, # 17-4801-80), Sca-1 PerCP-Cy5.5 (clone D7, #45-5981-80), 
Ter119 PE-Cy7 (Ter119, # 25-5921-81) (all eBioscience), CD4 PE (H129.19, # 553652), 
CD8 PE (53-6.7, #553032), CD19 PE (clone 1D3, #553786), Gr-1 PE (clone RB6-8C5, # 
561084), Ter119 PE (clone Ter119, # 553673), streptavidin APC-Alexa750 (#565144) (all 
BD) CD150 BV605 (clone TC15-12F12.2, #115927, BioLegend), streptavidin Qdot605 
(#Q10001MP, Invitrogen). Stainings for apoptosis detection were performed using 
Annexin V Fitc apoptosis detection kit (BD) according to manufacturer’s instruction. 
Before FACS measurement, cells were washed once with 10% FCS/HBSS, resuspended in 
100 µl 10% FCS/HBSS supplemented with 100 µl Sytox and analysed on a FACS Fortessa 
(BD) and data were evaluated using FACS Diva software (BD).  
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5.1.5. Molecular biology techniques  
5.1.5.1. Genotyping 
DNA was extracted from the YS or tail of the embryos or from the tail tip of adult mice. The 
tissue was incubated in 50 µl tail lysis buffer supplemented with 1.5 µl proteinase K over 
night at 56 °C. The next day 500 µl dH2O was added, the mixture boiled at 95 °C for 10 min 
and stored at 4 °C. For polymerase chain reaction (PCR) 1 µl of the DNA mixture was 
added to 19 µl of master mix for genotyping. Thermocycler conditions were: 3 min at 95 
°C, followed by 34 cycles of 20 s at 95 °C, 30 s at 60 °C and 45 s at 72 °C, finished with 5 
min 72 °C and hold at 12 °C. The finalized PCR product was complemented with 4 µl of 6x 
loading dye and 12 µl of the mixture was subjected to a 1% agarose gel for electrophoresis. 
Electrophoresis was carried out at 100V for 25 – 30 min. The agarose gel was 
photographed with Azure Imager.  
 
5.1.5.2. Protein isolation  
The FL was harvested as described above, incubated in 10 µl protein lysis buffer for 45 
min on ice and centrifuged at 4 °C at 300 g for 10 min to remove cellular debris. The 
protein containing supernatant was transferred to a new tube, snap frozen and stored at -
80 °C. Colorimetric quantification of protein concentration was determined by Protein 
Assay Kit, a method based on Lowry-Assay. The standard curve was prepared using 
bovine serum albumin (BSA) diluted in the corresponding lysis buffer, absorbance was 
measured at λ = 650 nm with a plate reader. 
 
5.1.5.3. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Protein samples were mixed with 2x Laemmli Buffer and boiled at 95 °C for 5 min. The 
SDS-gels were placed in electrophoresis chambers and covered with Tris base, acetic acid 
and EDTA buffer (TAE) buffer. 50 µg of FL lysates were loaded on the gels and samples 
were then subjected to gel electrophoresis at 20 mA until the protein size of interest was 
separated properly.   
 
5.1.5.4. Western Blot 
The proteins were transferred to nitrocellulose membranes in a semi-dry manner for 35 
minutes at 0.45 A in the Trans-Blot Turbo. After blotting, the membrane was blocked in 
5% milk block for 1 h at RT followed by incubation with primary antibody diluted in 5% 
milk block for 2 h at RT or overnight at 4 °C. Membrane were washed three times with PBS 
and incubated with horseradish-peroxidase (HRP)-conjugated secondary antibody diluted 
in 5% milk block for 1 h at RT. The membrane was washed extensively with PBS and 
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treated with Luminate Forte Western HRP Substrate for 3 minutes. The signal was 
detected by chemiluminescence on an Azure Imaging System. 
 
5.1.6. Statistics 
Statistical analysis was performed with SigmaPlot or GraphPad Prism. For comparisons 
unpaired two-tailed Student’s t-test was used. Differences between data sets with p < 0.05 
were considered statistically significant. Data are presented as means with error bars 
indicating standard deviation. Statistical significance is indicated by *p < 0.05, **p < 0.01, 
***p < 0.001. 
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5.2. Material 
Antibodies 
Table 3: Antibodies 
Primary antibody Company Catalogue Number 
CD11b BioLegend 101202 
CD146 Milteny Biotec 130-101-866 
CD3 BioLegend 100202 
CD31 BD Biosciences 102502 
CD32b R&D Systems AF1460 
CD68 BioLegend 137002 
cKit/CD117 R&D Systems AF1356 
Cre recombinase Synaptic systems 257003 
Desmin Abcam ab15200 
F4/80 BioLegend 123102 
Gata4 Santa Cruz sc-9053 
GFP/YFP Molecular Probes A-11122 
Liv2 MBL D118-3 
Lyve1 Reliatech 103-PA50S 
Stab2 Martens et al. 8 clone 3.1 
Ter119 BD Pharmingen 550565 
   
   
Secondary antibody Company Catalogue Number 
donkey anti-rabbit Cy2 Dianova 711-225-152 
goat anti-rat Cy3 Dianova 112-165-044 
donkey anti-goat Cy3 Dianova 705-165-147 
donkey anti-rat Cy3 Dianova 712-165-153 
bovine anti-goat Cy3 Dianova 805-165-180 
donkey anti-mouse Cy3 Dianova 715-165-151 
donkey anti-goat Cy5 Dianova 705-175-147 
sheep anti-mouse Cy5 Dianova 515-175-072 
donkey anti-rabbit Cy5 Dianova 711-175-152 
donkey anti-mouse Cy5 Dianova 715-175-151 
donkey anti-mouse Alexa Fluor 488 Dianova 715-485-150 
bovine anti-goat Alexa Fluor 488 Dianova 805-485-180 
donkey anti-mouse Alexa Fluor 488 Dianova 715-485-151 
goat anti-mouse HRP Dianova 115-035-166 
mouse anti-goat HRP Dianova 205-035-108 
donkey anti-rabbit HRP GE-Healthcare NA934 
Streptavidin labelled Alexa Fluor 488 Life Technologies S11223 
donkey anti-rat Cy2 Jackson Immunoresearch 712-225-153 
goat anti-rat Cy5 Jackson Immunoresearch 112-175-003 
Streptavidin labelled HRP Jackson Immunoresearch 016-030-084 
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Directly labelled antibody Company Catalogue Number 
CD11b-PE BD Pharmingen 553311 
CD11b-PerCP BioLegend 101230 
CD11c-APC BD Pharmingen 550261 
CD19-PerCP BioLegend 115532 
CD45.2-PE BD Pharmingen 560694 
F4/80-PE R&D Systems 5580P 
GFP/YFP-A488 Molecular Probes A-21311 
Ly6C-APC BioLegend 108412 
Ly6G-PE-Cy7 BD Pharmingen 560601 
 
Buffers and buffer recipes 
Ketamine/Xylazine anaesthesia 
10% Ketamine  1.2 ml 
2% Xylazine  0.8 ml 
PBS ad 10 ml 
 
Tail lysis buffer 
100 mM Tris HCL pH 8.0 - pH 8.5 20 ml 
0.5 mM EDTA 2 ml 
0.2% SDS 4 ml 
200 mM NaCl 8 ml 
dH2O ad 200 ml 
 
Master mix for genotyping 
Reaction Buffer Set for Taq DNA Polymerase (10X) 2 µl 
Deoxynucleoside triphosphate (dNTPs) mix, 10 mM each 0.4 µl 
Each Primer 0.6 µl 
DFS Taq DNA Polymerase 0.2 µl 
dH2O ad 19 µl 
 
1% Agarose gel 
In an Erlenmeyer flask agarose and 1x TAE buffer were mixed and heated in the 
microwave until gently boiling. After cooling down, Nancy was added and a gel was 
poured in an appropriate chamber. 
 
Agarose 1 g 
Nancy-520 10 µl 
1x TAE buffer 100 ml 
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4% PFA pH 7.2 
The PFA powder were weighted carefully under the laminar flow and added to dH2O. The 
mixture was stirred; the pH value was measured and increased by adding NaOH to pH 11. 
After a few minutes, the PFA powder has dissolved and 10x PBS was added. The pH value 
was adjusted to pH 7.2 by adding HCl. The 4% PFA solution was short term stored at 4 °C 
or aliquoted in 50 ml falcon tubes and stored at -20 °C. 
 
PFA powder 40 g 
10x PBS 100 ml 
dH2O 900 ml 
 
30% Sucrose 
Sucrose 150 g 
NaN3 10% 500 µl 
PBS 500 ml 
 
Peroxidase block 
H2O2 30% 100 µl 
NaN3 10% 200 µl 
PBS 30 ml 
 
β-galactosidase staining solution  
Reagent A 10 µl 
Reagent B 10 µl 
Reagent C 10 µl 
X-Gal solution 20 µg/ml in DMF 50 µl 
PBS 920 µl 
 
Immunofluorescent block buffer 
BSA 500 µg 
Donkey serum 500 µl 
NaN3 10% 10 µl 
PBS 10 ml 
 
Fixative for electron microscopy  
Formaldehyde 2% 
Glutaraldehyde 2% 
Tannic acid 0.5% 
MgCl2 1 mM 
Sucrose 2% 
in Sodium cacodylate 100 mM, pH 7.2 
 
FACS buffer 
NaN3, 10% 500 µl 
FCS 50 ml 
Dulbecco's phosphate buffered saline 500 ml 
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Protein lysis buffer 
NaCl 150 mM 
NP-40 1% 
Sodium deoxycholate 0.5% 
SDS 0.1% 
Tris / HCl (pH 8.0) 50 mM 
Sodium fluoride 10 mM 
EDTA 2 mM 
Protease inhibitor cocktail 4% 
 
Resolving gel 
During polymerization the resolving gel was covered carefully with isopropanol to avoid 
drying up.  
 
dH2O 5.0 mL 
30% Acrylamide 6.0 mL 
1.5 M Tris / HCl (pH 8.8) 3.8 mL 
10% SDS 0.15 mL 
10% APS 0.15 mL 
TEMED 6 μl 
 
Stacking gel 
After completion of the polymerization of the resolving gel, the isopropanol was 
demounted, the stacking gel was casted on top of the resolving gel and a comb was 
inserted. 
 
dH2O 1.72 mL 
30% Acrylamide 0.5 mL 
0.5 M Tris, pH = 6,8 0.76 mL 
10% SDS 0.03 mL 
10% APS 0.03 mL 
TEMED 3 μl 
 
Milk block 
Milk powder 5 g 
PBS 100 ml 
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Chemicals and reagents 
Table 4: Chemicals and reagents 
Name Company 
4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) Life Technologies 
Acetone Roth 
Acrylamide, 30% Bio-Rad 
AEC Substrate Chromogen DAKO 
Agarose Sigma 
Ammonium persulfate Sigma 
Ammonium chloride NH4Cl Roth 
Biocoll Biochrom 
Bovine serum albumin (BSA) Fitzgerald 
DFS Taq DNA Polymerase Bioron 
DNA Gel Loading Dye (6X) Thermo Fisher 
DNA Ladder Thermo Scientific 
dNTPs mix, 10 mM each Fermentas 
Donkey serum Dianova 
DPBS [-]CaCl2 [-]MgCl2 Life Technologies 
Ethanol Roth 
Ethylenediaminetetraacetic acid (EDTA) Sigma 
Faramount aquaeus mounting medium DAKO 
Faramount mounting medium, aqueous  DAKO 
Fetal calf serum (FCS) Life Technologies 
Fluorescent mounting medium DAKO 
Hydrogen peroxide H2O2 Sigma 
Isofluorane (Forene® 100%) Abbot 
Ketamine 10% Medistar 
Laemmli Buffer Bio-Rad 
Milk powder  Roth 
Nancy-520 Sigma 
NP-40 Fluka 
PageRuler prestained protein ladder Fermentas 
Paraffin Roth 
Paraformaldehyde Roth 
PBS powder without Ca2+, Mg2+ Life Technologies 
Protease inhibitor cocktail Roche 
Proteinase K (10 mg/ml) Sigma 
Reaction Buffer Set for Taq DNA Polymerase (10X) Bioron 
Rompun 2% (Xylazine) Bayer 
Sodium azide NaN3 Sigma 
Sodium chloride NaCl Sigma 
Sodium deoxycholate Sigma 
Sodium dodecyl sulphate (SDS) BioRad 
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Sucrose BioFroxx 
TAE buffer 10x Roth 
Tetramethylethylenediamine (TEMED) GenAxxon 
Tri-HCl Sigma 
Triton X-100 Sigma 
Tween Sigma 
Xylene Sigma 
 
Consumables 
Table 5: Consumables 
Name Company 
Adhesion microscope slides SuperFrost Plus® Langenbrinck 
Butterfly needle, 25 G Seidel Medizin 
Cell strainer70 µm and 100 µm BD Biosciences 
Cryomolds Sakura 
Falcon tubes Becton Dickinson 
Lithium/Heparin microvettes 500 µl Sarstedt 
Micropipettes, intraEND, 20 µl Blaubrand 
Nitrocellulose membrane Bio-Rad 
OCT compound  Sakura 
Paraffin embedding cassettes Sarstedt 
 
Instruments 
Table 6: Instruments 
Name Company 
Analytical balance R300S Sartorius 
Azure Imager C400 Azure Biosystems 
Confocal laser scanning microscope SP5 DS  Leica 
Cryotome CM3050S Leica 
Electron microscope 910 Carl Zeiss 
FACS-Canto™ II BD Biosciences 
Gel electrophoresis system Mupid One 
Microtome RM2065 Leica 
Multi-photon laser scanning microscope SP MP Leica 
Nanodrop 2000 Thermo Scientific 
pH Meter FG2/EL2 Mettler Toledo 
Plate reader infinite 200pro Tecan 
Table centrifuge 5415D Eppendorf 
Thermoblock Thermomixer C Eppendorf 
Thermocycler T100 BioRad 
Top-loading balance PT2100 Sartorius 
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Trans-Blot Turbo BioRad 
Transmitted Light Bases TL3000 Ergo microscope Leica 
Upright microscope Eclipse Ci-E Nikon 
Upright motorized microscope Eclipse Ni-E Nikon 
Vortex Genie-2 Scientific Industries 
 
Kits 
Table 7: Kits 
Name Company Catalogue number 
Avidin/biotin blocking kit Vector Laboratories #SP-2001 
Protein Assay Kit BioRad 5000112 
β - Galactosidase Reporter Gene Staining Kit Sigma #GALS-1KT 
 
Mouse strains 
Table 8: Mouse strains
Name Official name Company / reference 
Gata4 79 Gata4tm1.1Sad The Jackson Laboratory / #008194 
R26LacZ 92 Gt(ROSA)26Sortm1Sor The Jackson Laboratory / #003474 
R26YFP 93 Gt(ROSA)26Sortm1(EYFP)Cos The Jackson Laboratory / #006148 
Stab2-cre B6.Stab2tg1.2cre 
B6.Stab2tg1.3cre 
 
Clec4g-cre B6.Clec4gtg1.1cre   
Rag2-/-;γc-/-;KitW/Wv  Rag2-/-;γc-/-;KitW/Wv  Waskow et al. 117 
 
Primer 
Table 9: Primer 
Name Sequence 5' -> 3' 
Gata4_forward CCC AGT AAA GAA GTC AGC ACA AGG AAA C 
Gata4_reverse AGA CTA TTG ATC CCG GAG TGA ACA TT 
iCre_forward AAG AAC CTG ATG GAC ATG TTC AGG 
iCre_reverse TCT GTC AGA GTT CTC CAT CAG GGA 
LacZ_common AAA GTC GCT CTG AGT TGT TAT  
LacZ_mutant GCG AAG AGT TTG TCC TCA ACC  
LacZ_wildtype GGA GCG GGA GAA ATG GAT ATG  
YFP_common AAA GTC GCT CTG AGT TGT TAT  
YFP_mutant AAG ACC GCG AAG AGT TTG TC 
YFP_wildtype GGA GCG GGA GAA ATG GAT ATG  
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Software 
Table 10 Software 
Name  Version Company 
FlowJo Version 10.4.2 Tree Star, Inc. 
GraphPad Prism Prism 5 GraphPad Software 
ImageJ ImageJ 1.50i National Institutes of Health 255 
SigmaPlot SigmaPlot 11.0 Systat Software 
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